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 Ect2 is a member of the Dbl family of proto-oncogenes and exhibits exchange 
activity for Rho-GTPases. It is over-expressed in dividing cells and tumours such as 
gliomas, and thus implicated in oncogenesis. However, a mechanism that underpins Ect2 
oncogenecity is not clear. Firstly, in this study, analysis of Ect2 function in glioma cells 
reveals a role in G1/S progression. Ect2 suppression by siRNA abrogates G1/S 
progression in quiescent glioma re-stimulated with serum, and is accompanied by high 
levels of the CDK inhibitor p27Kip1 and reduced Rb hyper-phosphorylation. In contrast, 
Ect2 over-expression in quiescent cells suppresses p27Kip1 and induces serum-
independent DNA synthesis. Ect2 mediates p27Kip1 suppression through decreased 
mRNA half-life and protein degradation; inhibition of the proteasome activity abrogates 
p27Kip1 reduction. Furthermore, Ect2 mediates Rb hyper-phosphorylation through RhoA 
activation. Ect2 over-expression increases RhoA activation, which is underscored by 
increased association between Ect2 and activated RhoA. These findings indicate that Ect2 
oncogenecity may be linked to its RhoGEF function in regulating the G1/S progression 
through degradation of the key CDK inhibitor p27Kip1. In addition, the DH domain of 
Ect2 is demonstrated to be the minimum requirement for the inactivation of the p27Kip1 
tumour suppressor.  
 
 Secondly, a functional relationship between Ect2 over-expression and glioma 
grading is established. Ect2 over-expression promotes glioma cell invasion, and it is 
likely that Ect2-mediated G1/S progression can contribute to increased cell proliferation 
 viii 
associated with high grade gliomas. In addition, down-regulation of Ect2 markedly 
inhibits glioma cell proliferation and clonogenecity in both TMZ-sensitive and –resistant 
cell lines. Taken together, these results validate the use of Ect2 as a biomarker for 
accurate glioma grading, as well as forming the basis for Ect2 as a candidate for targeted 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1  Malignant Gliomas 
 
 Glioblastoma multiforme (GBM) is the most common form of primary central 
nervous system tumours, occurring at a frequency of 5 to 8 in every 100,000 population. 
They are also the most fatal, with patients suffering from the most malignant forms 
surviving about a year [1-3]. Gliomas can be detected by CT and MRI scans. They may 
arise sporadically and in a non-inherited manner. GBMs are often necrotic and 
haemorrhagic tissue masses, with a heterogeneous population containing tumour cells, 
macrophages and endothelial cells that are over-proliferating [3]. They are also 
characterised by extensive vascularisation [2]. 
 
1.1.1 Grading of gliomas 
 
 Gliomas can be classified into two types according to their histology: 
oligodendrogliomas and astrocytomas. The former is identified by the presence of cells 
with small nuclei, low cytoplasmic content and the absence of the glial fibrillary acidic 
protein (GFAP).  The latter contains cells with high cytoplasmic content and expresses 
GFAP [4]. Another difference is that astrocytomas have a high capacity for invasiveness 
as well as progression to malignancy while malignant oligodendrogliomas make up only 
a minor percentage.  
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Astrocytomas fall into the three-tiered system corresponding with WHO grading: 
low grade astrocytoma (WHO Grade II), anaplastic astrocytoma (WHO Grade III) and 
glioblastoma multiforme (GBM) (WHO Grade IV) [5]. The general grading criteria 
includes histopathological features such as cellularity, degree of cellular pleomorphism, 
proliferation index indicated by mitotic activity, prominence of microvasular structures 
and necrosis [6]. 
 
1.1.1.1 Issues encountered in the proper classification of gliomas 
 
There exist two caveats for proper classification of gliomas. The first issue to 
consider in the classification of gliomas is that of their inherent tumour heterogeneity [7]. 
Studies show that based on proliferation and histological markers, multiple regions within 
the same tumour tissue can vary significantly. This results in grading inaccuracies. Thus, 
it is important to identify markers suitable for astrocytoma grading and reduce the margin 
for error. The second issue is the technique used in determining proliferative capability. 
The first method of measuring glioma proliferation index is Ki-67 staining [8, 9]. Ki-67 is 
a protein required for proliferation [10]. Disruption of Ki-67 function by micro-injecting 
antibodies results in delay of the cell cycle [11]. Expression of the protein is regulated 
throughout cell cycle and it is absent in quiescent cells, making it a suitable marker for 
measuring cellular proliferation in both resected and histological samples [12]. 
 
However, the feasibility of Ki-67 staining is limited by the integrity of the tissue 
samples. Immunohistochemistry can only be performed on freshly resected tumours or 
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frozen tissues but not formalin-fixed tissues as fixation can significantly affect staining. 
This is circumvented with the use of the MIB-1 monoclonal antibody which allows 
accurate staining in formalin and paraffin-preserved samples [13]. The use of Ki67-MIB1 
labelling index is commonly used as a marker for glioma grading to distinguish with high 
accuracy between the low grades (I and II) and higher grades gliomas (III and IV) [14]. 
However, it is a poor indicator of the difference between grades III and IV gliomas, thus 
limiting its clinical value in the accurate diagnosis of GBMs [15].   
 
The second method of measuring proliferation is to detect cells in S phase using 
BrdU incorporation [16]. BrdU is an analogue of thymidine and is actively taken up by 
cells during DNA synthesis. An antibody against BrdU can be used to determine the 
percentage of cells actively dividing [17]. However, this method poses the limitation that 
only resected tissue samples can be evaluated since the dividing cells would need to be 
pulsed with BrdU prior to detection. To overcome this, BrdU labelled with 76Br is 
proposed as a tracer for positron emission tomography (PET) [18]. Since majority of 
radio-active signal emitted from the metabolized 76Br-BrdU tracer is in the form of 76Br-
bromine rather than from 76Br-BrdU, dialysis is required to eliminate this background 
signal from 76Br-bromine. A significant elimination of 76Br-bromine after dialysis is 
observed in pigs (~50%) with 70 – 80% radio-activity from 76Br-BrdU detected. 
However, the actual level of radio-activity from 76Br-BrdU recovered in humans is only 
9%, indicating that both dialysis regime and tracer have limited clinical use [18, 19]. 
Also, as glioma cell proliferation is the result of complex cross-talking between several 
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signalling pathways, the measurement of S phase cells may not be an accurate 
determinant of cell growth [20]. 
 
1.1.1.2 Criteria for selecting candidate genes as glioma biomarkers 
 
Given the problems faced in accurate classification of gliomas and their diagnosis, 
it is important to uncover new targets. Transcriptome profiling has yielded a plethora of 
genes potentially involved in glioma progression [21-24]. These are attractive targets for 
development of glioma biomarkers. However, proper selection criteria must be applied to 
the identification and development of potential targets into clinically valuable tools. The 
choice of candidates should take into consideration the ability to overcome heterogeneity 
of the GBMs and exhibit distinct expression patterns among similar grades (e.g. Grade III 
vs. Grade IV). Below are two examples of genes that meet these requirements.  
 
 As GBMs are characterized by increased proliferation, cell cycle proteins such as 
the mini chromosome maintenance protein 7 (MCM7) are likely candidates for disease 
diagnosis. MCM7 is required for DNA replication [25]. It is over-expressed in aggressive 
cervical and prostate cancers [26, 27]. Over-expression of Mcm7 is also implicated in the 
development of skin tumours [28]. The use of Mcm7 as a diagnostic marker is validated 
in both low and high grade gliomas and Mcm7 staining is a more reliable indication of 
proliferation compared to Ki-67 [29]. In addition, Mcm7 staining intensity also correlates 




Another hallmark of glioblastomas is increased invasiveness. This is mediated by 
the matrix metalloproteinases (MMP) which are essential for glioma cell invasion by 
degrading the extra-cellular matrix and activating growth factors required for glioma cell 
invasion [31-33]. MMPs are highly expressed in GBMs and correlate with tumour 
grading [34]. Individual members such as MMP2 and MMP9 have demonstrated strong 
correlation with particular subtypes of gliomas as well as the degree of malignancy, 
making them valid markers for more accurate glioma classification [35-37].  
 
 Apart from reinforcing the need for proper selection criteria of potential GBM 
biomarkers, these examples also highlight the current trend in biomarker identification 
and validation. The candidate genes should demonstrate a unique and specific function in 
promoting glioma progression as well as robust grade-specific staining and clinical 
correlation. These additional factors should be considered when selecting targets as GBM 
biomarkers. 
 
1.1.2 Temozolomide in the treatment of malignant gliomas 
 
 Temozolomide (TMZ) represents a new class of second-generation 
imidazotetrazine prodrugs and has shown promise in treating GBMs and other difficult-
to-treat tumours [38-40]. It exhibits broad-spectrum anti-neoplastic activity in mouse 
tumour models, as well as a variety of malignancies such as glioma, melanoma, sarcoma 
lymphoma and leukemia [41, 42]. TMZ shows distribution to all tissues and penetration 
into the CNS, has the ability to cross the blood brain barrier and does not require hepatic 
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metabolism for activation [43, 44]. TMZ is converted to the highly reactive methylating 
agent 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) by water, degrades to 
the methyldiazonium cation and is excreted as 4-amino-5-imidazole-carboxamide [45] 
via the kidneys [46]. MTIC is the species responsible for methylation of DNA [47]. 
 
 The use of TMZ in management of malignant gliomas has significant advantages 
over other agents. TMZ is associated with low toxicity and significant improvement in 
survival rate. Progression free rate is 21% at 6 months compared to 8% at 6 months for 
procarbazine [48]. TMZ can be taken orally and is well tolerated with minimal 
myelosuppression and non- haematological toxicity [48, 49]). The ease of administration 
has also made it suitable for treatment of paediatric gliomas where chemotherapy is the 
primary modality prescribed [50]. These findings have propelled TMZ to be a standard 
treatment regime for malignant gliomas. 
 
1.1.2.1 Chemo-resistance to TMZ in gliomas 
  
 The main mechanism of TMZ-induced toxicity is by DNA methylation. The most 
commonly-induced lesions are methylation of N7 of guanine (N7-MeG), N3 of adenine 
(N3-MeA) and O6 of guanine [47]. The N3-MeA and N7-MeG are efficiently repaired by 
BER, whereas O6-MeG is the major contributor to TMZ toxicity despite its low 




enzyme, which specifically removes alkyl groups. Thus TMZ efficacy is dependent on 
the levels of MGMT present in the tumours – cells that have high levels of the enzyme 
will be more resistant to the cytotoxic effects of TMZ. Hegi and colleagues demonstrated 
the use of the methylation status of the MGMT promoter as a prognostic tool for 
predicting patient response to TMZ chemotherapy [51]. Epigenetic silencing of the 
MGMT gene through promoter methylation is associated with decreased enzyme levels 
and reduced DNA lesion removal [52, 53]. These studies show that when patients with 
methylated MGMT promoter status are given combination of TMZ and radiation 
treatment, their median survival increase from 15.3 months with just radiation treatment 
alone to 21.7 months with radiation and TMZ combination therapy (p=0.05). MGMT- 
mediated chemo-resistance can be circumvented by the use of the free base O6-benzyl 
guanine (O6-BG), which depletes pools of MGMT in the cells [54, 55]. 
 
 In the event that the methylated O6-MeG is not removed, it is paired with a 
thymine instead of cytosine during semi-conservative DNA replication. This activates the  
mismatch repair (MMR) system which then excises the mismatched thymine but not the 
methylated guanine, thus resulting in the erroneous thymine to be reinserted [56]. This 
generates futile cycles of excision and DNA nicking, eventually leading to a cell cycle 
arrest at the G2/M boundary and subsequently mitotic catastrophe (Figure 1.1) [57]. The 
DNA double strand breaks [58] generated also induce apoptosis as cells deficient in DSB 
repair are more susceptible to TMZ-induced apoptosis [59]. Ultimately, the ability of the 
cell to enter a G2/M arrest following TMZ-induced damage rests on the presence of the 
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Figure 1.1 Proposed mechanism for TMZ-induced cytotoxicity. TMZ induces 
alkylated lesions at N7 guanine, N3 adenine and O6 guanine, of which the last is the most 
lethal albeit in least abundance. Upon recognition of the O6-MeG:T mismatch by MSH2 
and MSH6, the mispaired thymine is excised by exonucleases while RPA coats the single 
stranded DNA. PCNA and DNA polymerase then proceed to fill in the gap with yet 
another thymine, resulting in futile cycles of repair, and subsequent accumulation of 




dependent on p53 status [57]. Furthermore, either the expression of inactivated p53 
protein or pharmacological inhibition of protein function in astrocytic glioma cells 
significantly enhanced sensitivity towards TMZ, demonstrating the importance of a 
functional p53 protein [60]. 
 
 MSH2 is a MMR protein that recognizes mismatch lesions [61]. Cells with low 
MSH expression are resistant to the cytotoxic effects of TMZ [62]. Mutations in another 
MMR protein MLH1 renders colorectal carcinoma cell lines insensitive to TMZ even 
after depleting MGMT with O6-BG. This indicates that MMR mutations are able to over-
ride MGMT in conferring resistance to TMZ [63]. In gliomas, reduced expression and 
mutations in MMR genes are also reported and are associated with chemo-resistance [64, 
65]. 
 
1.1.2.2 Current strategies to overcome TMZ resistance 
 
 As discussed in earlier sections, high levels of MGMT significantly attenuate 
TMZ cytotoxicity. To overcome this resistance, O6-BG is used to deplete cellular levels 
of MGMT. In human colon carcinoma cells, pre-incubation with low levels of O6-BG 
efficiently inactivate MGMT, resulting in increased sensitivity to alkylating agents [66, 
67]. It is further shown that O6-BG achieves similar sensitization to TMZ in human 
glioma cells [38, 68]. However, Phase I trials of O6-BG pre-treatment with TMZ have 
yielded mixed results. Firstly, different groups report different optimal treatment regimes 
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of O6-BG. Schold and colleagues propose that administration of 120 mg/m2 of O6-BG for 
6h is sufficient to observe a depletion of MGMT in resected GBMs, whereas Friedman et 
al report that administration of 100 mg/m2 of O6-BG for 18h has a higher efficacy not 
observed at 6h [69, 70]. Another group also proposes a biphasic administration of O6-BG, 
with an initial dose of 120 mg/m2 for 1 h followed by TMZ (1h). This is followed by a 
continuous infusion of 30 mg/m2 O6-BG for another 48h [71]. With these conflicting 
reports, the issue of dosage and treatment regime must be resolved in order to establish a 
proper foundation for the commencement of Phase II trials. 
 
 Secondly, systemic administration of O6-BG has severe side effects. This is 
reported in two of the clinical studies mentioned above. Patients exhibit severe myelo-
suppression upon administration of the alkylating agent following O6-BG infusion, thus 
greatly compromising the dose of the alkylating drug.  Koch et al has attempted to 
overcome this caveat by introducing O6-BG locally through the use of a surgically 
implanted Ommaya reservoir [58].  Local administration of O6-BG does not result in 
significant systemic or localized toxicity. However, the strategy has not improved patient 
prognosis as the patient subsequently developed three recurrences with increasing 
MGMT levels leading to death 5 years after diagnosis [58]. Due to these reasons, the 
clinical potential of O6-BG in attenuating TMZ resistance is greatly limited. 
 
 MMR deficiency is another cause of TMZ chemo-resistance in gliomas. But apart 
from MMR, TMZ also activates the base excision repair (BER) pathway. BER removes 
the N7-MeG and N3-MeA lesions instead of the O6-MeG lesions [72, 73]. Thus, 
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disruption of BER in MMR-deficient cells can increase sensitivity to alkylating agents 
[74]. Poly-(ADP-ribose) polymerase I (PARP-1) is a sensor of DNA breaks resulting 
from base excision activity, through interaction with XRCC1 and DNA polymerase β and 
facilitates repair [75]. The inhibition of PARP-1 has enhanced sensitivity to alkylating 
agents like TMZ in gliomas and other cancer types [76-79]. Pre-clinical studies with 
PARP-1 inhibitors show little myelo-toxicity in xenograft models, suggesting that the 
drug may be well-tolerated in humans [80]. As Phase I clinical trials for two PARP-1 
inhibitors INO-1001 and AG14699 began in 2005, data demonstrating the efficacy of this 
strategy is not available [81, 82].  
 
 In summary, the limited success of circumventing TMZ-chemoresistance begets 
investigations into better targets. These genes should have a specific function in either 
promoting glioma survival or progression, or confer chemo-resistance through TMZ-
induced stress response pathways. Thus, further studies into cellular responses elicited by 
TMZ in human glioma cells will shed light in this aspect. 
 
1.2 Cell cycle control and Cancer 
 
 A cell undergoes numerous rounds of division in its lifetime. Entry into each 
phase of the cell cycle is a tightly regulated process at various phases in order to ensure 
that basic requirements such as cell size, nutrient sufficiency, accurate replication and 
distribution of genetic material are met. In the event that errors occur, checkpoints are 
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activated, halting cell cycle progression and buying time to facilitate repair. These 
checkpoints are essential for error-free cell replication and failure to execute these 
programs may lead to severe consequences such as cancer.  
 
The cell cycle is divided into four distinct phases: the initial gap phase (G1) where 
cells await diverse signals such as growth factors and the environment to decide if they 
should commit to cell division. The second phase is where cells proceed to replicate 
DNA (S), followed by another gap phase (G2). Here, cells take stock of proteins and 
cellular material to be distributed between the two daughter cells and also to provide time 
for repair of any errors incurred during DNA replication. The last phase is mitosis (M), 
where the physical separation of DNA, now condensed into chromosomes, and 
cytoplasmic and nuclear material occur via a process known as cytokinesis [83]. Here, 
checkpoints are also in place to ensure that the same number of chromosomes is allocated 
to each daughter cell (Figure 1.2).  
 
1.2.1 Cyclins and Cyclin-dependent kinases 
 
 Cyclins belong to a family of proteins that regulate cell cycle, transcription as 
well as differentiation. They represent the regulatory subunit of the cyclin-CDK 
complexes and direct the catalytic activity of the cyclin-dependent kinases. Each cyclin 
can associate with one or more CDKs and act together to phosphorylate downstream 
substrates. Cyclins are first characterized in early embryonic cell cycles, where there are 












































during interphase and decrease during mitosis while the levels of cyclin E remain 
constant throughout the cell cycle. By re-introducing recombinant proteins into cyclin-
depleted cell extracts, it is clearly demonstrated that while cyclin E supports DNA 
replication and centrosome duplication, cyclin A promotes both DNA synthesis as well as 
mitosis, and cyclin B induces only mitosis [84]. The G1 cyclin D was originally 
characterized in budding yeast (Clns 1–3) but the mammalian counterpart was only 
successfully isolated after extensive screening for cDNAs capable of rescuing the yeast 
cln mutants [85, 86]. Apart from its expression which is tightly linked to cell cycle, the 
use of neutralizing antibodies against cyclin D1 show that DNA synthesis is inhibited, 
thus placing cyclin D1 upstream of other cyclins, providing clear evidence that cyclin D1 
is required for G1 in mammalian cells [87]. 
 
 Cyclins are identified by the presence of a 100-amino acid motif known as the 
“cyclin box” which enables the binding of cyclin to its kinase partner, the CDK [88]. In 
turn, the CDKs require the presence of a cyclin in order to be activated [89]. The CDKs 
share a similar motif among themselves, the PSTAIR region, which is exposed on the 
surface of the enzyme and is required for interaction with cyclins.  Mutations in this 
region have been shown to disrupt cyclin binding [89].  
 
1.2.2 CDK inhibitors 
 
CDK inhibitor proteins are small proteins (15 to 27 kDa) that stoichiometrically 
bind and inactivate specific cyclin-CDK complexes. There are two distinct families, 
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p21Cip1 and p16INK, which have different substrate specificities and binding modes. The 
p21 family of inhibitors (p21Cip1, p27Kip1 and p57Kip2) binds the cyclin-CDK complexes 
required for cell cycle progression and form ternary complexes, while the p16INK (p16, 
p15, p19) family of inhibitors binds specifically to CDKs 4 and 6 to form binary 
complexes [90]. In addition to regulating the cell cycle by inhibiting the cyclin-CDK 
complexes, over-expression of p16INK can prevent phosphorylation of the RNA pol II C-
terminus domain in a CDK7-dependent manner, thus inhibiting transcription [91, 92].  
 
The p21Cip1 family of inhibitors bind and block the activity of all the cyclin-CDK 
complexes albeit with different degrees of inhibition [93]. p21 itself is under the control 
of the tumour suppressor p53 and is up-regulated in response to irradiation-induced DNA 
damage and cellular senescence [94-97]. p21Cip1 expression can also be induced by p53 in 
response to oxidative stress in a p38 MAPK-dependent manner [98]. Upon these various 
stimuli, p21Cip1 binds to both cyclin D-CDK4/6 and cyclin E-CDK2 complexes, 
preventing the phosphorylation of Rb [99, 100]. This results in the sustained inactivation 
of the transcription factor E2F1 and suppressed transcription of S phase-related genes. 
 
p27Kip1 is more commonly characterized as the inhibitor of cyclin E/A-CDK2 
complex inhibitor and has a strong anti-proliferative effect [101, 102]. Expression of 
p27Kip1 with antisense cDNA suppresses quiescence in mouse fibroblasts, indicating that 
it is required for exit from cell cycle [103, 104]. p27Kip1 protein expression is cell cycle-
dependent, with the protein levels decreasing as cells progress through G1. This is 
mediated by proteasome-dependent degradation as well decreased mRNA stability [105]. 
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Proteasome-mediated p27Kip1 degradation is dependent on the Skp2 ubiquitin ligase 
[106]. The reduction in p27Kip1 is essential for cell cycle progression and its suppression 
is dependent on the presence of growth factors [107]. Cells with constitutively active 
growth factor signalling pathways often have low p27Kip1 levels and exhibit excessive cell 
proliferation [108, 109]. 
 
 Although p21Cip1 and p27Kip1 are well established as cyclin-CDK inhibitors, they 
also have a novel role in facilitating the assembly of cyclin-CDK complexes at lower 
levels [110]. It is proposed that these trimeric complexes are active and inhibition only 
occurs at higher concentrations of the inhibitors. Consistent with this hypothesis, 
knockout experiments show that cells lacking in either p21Cip1 or p27Kip1 are unable to 
form active cyclin D/CDK4-6 complexes [111].  
 
1.2.3 G1 control and cancer 
 
 Control of the cell cycle during the G1 phase is of great importance since this is 
the window where cells receive external cues to either halt or proceed with duplication 
and subsequent separation of genetic material. The increase in physical size is 
accompanied by activation of signalling cascades promoting the expression of genes 
required for DNA synthesis. While several different types of growth factors and their 
receptors can be activated, they all converge at phosphorylation of Rb at late G1 [112]. 
With its hyper-phosphorylation, Rb is released from the transcription factor E2F1, 




1.2.3.1 Cyclin deregulation 
 
 During G1 phase, Cyclin D forms an active complex with either CDK4 or CDK6. 
Since cyclin D transcription is stimulated by growth factors, this complex functions as a 
sensor of mitogenic signals, and is required for the phosphorylation and inactivation of 
Rb [115]. The consequence of this event is progression through the restriction point 
whereby E2F1 is activated. Subsequently, the transcription of S phase genes is induced 
with Cyclin E being one of the transcriptional targets. Cyclin E then complexes with 
CDK2 and proceeds to drive the progression from G1 to S phase by phosphorylating Rb 
and promoting further E2F1 transcriptional activity [116, 117]. As a result, Rb is 
maintained in an inactive state via a positive regulatory feedback loop [118]. 
  
 Since the cyclin-CDK complexes are essential for cell cycle progression, the 
deregulation of cyclin or their catalytic CDK subunits is potentially oncogenic. 
Commonly observed in tumours is the over-expression of cyclin D and cyclin E [119-
126]. Chromosomal translocation and point mutations are also reported. 
Immunohistochemical studies demonstrate that translocation between chromosome 
11q13, where the cyclin D1 locus CCND1 resides, and chromosome 14q32 results in 
over-expression of cyclin D1. In some cases, trisomy 11 was also observed [127]. For 
example, such t(11:14) translocation of the cyclin D1 locus is observed in a subset of B 

























Figure 1.3. Events involved in the regulation of the G1/S transition. Hyper-phosphorylation by Cyclin D-cdk4/6 complexes 
releases E2F from Rb inhibition. Activated Cyclin E-cdk2 complex then regulates E2F activity through a positive feedback loop, at 
the same time, targeting p27Kip1 for ubiquitin-mediated degradation. Small amounts of p21Cip1 and p27Kip1 can facilitate the formation 
of cyclin D complexes and inhibit at higher levels. While p27Kip1 is a physiological CDK inhibitor, p21Cip1 is regulated mainly by p53 
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untranslated region (UTR) or mutations in the gene locus itself in mantle cell lymphoma 
gives rise to truncated transcripts with increased half-life, thereby increasing protein 
expression [129]. Amplification of the CDK6 locus (7q22) is also detected in T-cell 
lymphoma [130]. Wolfel et al show that a point mutation from Arg24 to Cys24 renders 
the CDK4 subunit insensitive to inhibition by p16INK [131]. These findings underscore 
the importance of CDK inhibitors and their interaction with cyclin-CDK complexes. 
 
 The transcription of cyclin D and E is dependent on growth factor signalling. For 
example, cyclin D1 transcription is induced by almost 4-fold in prostate cancer cells after 
stimulation with epidermal growth factor (EGF) [132]. Similar induction is observed in 
pancreatic cancers stimulated with EGF [133]. Over-expression of cyclins is also linked 
to pancreatic duct cell carcinogenesis [134]. The deregulation of cyclin expression by 
growth factor signalling is discussed in greater detail in later sections. 
 
1.2.3.2 Regulation of the p27Kip1 CDK inhibitor 
 
 Apart from deregulation of cyclin and CDKs, the lack of inhibition on CDK 
activity can also contribute to neoplastic growth. For instance, loss of the CDK inhibitor 
p27Kip1 is associated with tumour progression and poor prognosis [135-143]. Inactivating 
mutations of p27Kip1 are few, suggesting that loss of p27Kip1 may be the result of 




 p27Kip1 is regulated post-transcriptionally. Its mRNA levels remain constant 
throughout cell cycle while protein levels fluctuate. Cells treated with inhibitors of the 
26S proteasome accumulate high levels of p27Kip1, indicating that suppression of this 
CDK inhibitor is achieved through ubiquitin-mediated protein degradation [145]. It is not 
surprising that untimely degradation of p27Kip1 can lead to derailing of the cell cycle 
machinery. p27Kip1 inhibits cyclin E-CDK2 but facilitates the assembly of cyclin D-
CDK4/6 complexes at low concentrations [101, 146]. Cyclin E synthesis increases due to 
increased Rb hyper-phosphorylation, resulting in the formation of more active cyclin E-
CDK2 complexes. These active cyclin E-CDK2 complexes in turn phosphorylate p27Kip1 
at Thr-187 [147, 148]. Such a phosphorylation event is essential for p27Kip1 degradation 
by the proteasome, as the non-phosphorylatable mutant is stable compared to wild-type 
p27Kip1 [147]. Subsequently, the ubiquitin E3 ligase SCFSkp2 binds to p27Kip1 
phosphorylated on Thr-187 and targets it for ubiquitinylation [106, 149, 150].  
 
 Enhanced degradation of p27Kip1 by the proteasome is reported in several tumour 
types [151, 152], indicating that failure to restore p27Kip1 in the cell can potentially lead 
to tumourigenesis. This is further reinforced by data showing that high levels of Skp2 
correlate with tumour malignancy in lymphomas [153]. However, transgenic mice with 
Skp2 over-expression in the T cell lineage do not develop tumours. Instead, the 
development of T cell lymphoma is induced only when these transgenic mice are crossed 
with those carrying an activated N-Ras gene, and occurs at a much higher rate than with 
N-Ras transgene alone [153]. Furthermore, enhanced p27Kip1 degradation is a target of 
Ras-induced cellular transformation as well as in Ras-mediated signalling in response to 
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growth factors [154, 155]. The addition of platelet-derived growth factor (PDGF) is able 
to induce a transient decrease in p27Kip1 protein levels, accompanied by increase in 
Cyclin E-CDK2 activation [156]. These results indicate a co-operative effect of loss of 
cell cycle control and proliferative signals from Ras pathways in oncogenesis [157].  
 
1.2.3.3 Growth factor signalling in cancer 
 
  Rb hyper-phosphorylation is the result of stimulation by growth factors and 
underpinning the role of mitogenic signalling in cell cycle control and cancer. The ligand 
binds to its receptor and activates the mitogen-activated protein kinase pathway (MAPK), 
followed by a series of phosphorylation events leading to the activation of key signal 
transducers and eventually to activation of transcription factors in the nucleus.  
 
 Many tumours over-express or have constitutively active mutants of growth factor 
receptors. The amplification of the EGFR gene is observed in half of GBMs [158]. 
Hyper-activation of EGFR is attributed to truncation of the extra-cellular domain in 50% 
of the cases resulting in a constitutively active mutant [159, 160]. Cells over-expressing 
the mutant EGFR have a survival advantage over wild-type cells under low serum 
conditions and they are able to significantly induce tumourigenesis in both subcutaneous 
and intra-cranial models of nude mice [161]. Enhanced tumour formation is also 
accompanied by increased proliferation, which is indicated by hyper-activation of the Ras 




 The consequence of growth factor signalling is gene transcription activation 
leading to cellular proliferation. One of the most direct effects of aberrant growth factor 
signalling is the increase in cyclin expression as the induction of cyclins is dependent on 
mitogenic signalling.  Transcriptional activation of cyclins D and E is dependent on 
mitogenic signals and mutations resulting in constitutively active mitogenic signalling 
also contribute to the over-expression of cyclins in tumours. Kersting et al show that 
over-expression of the EGFR in breast phylloides tumours correlate with increased 
Cyclin E expression [163]. In non-small cell lung cancer cell lines, Kobayashi and 
colleagues show that cyclin D expression is elevated in cells harbouring EGFR mutations 
but not in EGFR wild-type cells [164]. This is confirmed by Sasaki et al when they show 
that cyclin D mRNA is elevated in lung cancer patients with EGFR mutations [165]. 
Cyclin D up-regulation by EGFR is mediated mainly through the phosphotidyl-inositol-3-
kinase (PI3K) and Akt signalling pathway. Inhibition of EGFR with AG1478 suppresses 
PI3K and Akt signalling activation and results in reduction of the levels of cyclin D 
mRNA in breast carcinoma [166].  
 
 ErB2 (Neu, HER-2), a growth factor receptor related to EGFR, also up-regulates 
cyclin D in breast cancers. This up-regulation is required for ErB2-mediated 
transformation, albeit through different signalling pathways [167]. Constitutively active 
ErB2 (NeuT) is expressed in MCF7 breast cancer cell lines and stimulates a significant 
increase in cyclin D protein levels as well as cyclin D promoter activity. The concurrent 
expression of an inactive Ras mutant (N17Ras) neutralizes this phenotype. The Rho 
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signalling pathway, which is downstream of Ras is also involved in the above process. 
Expression of the dominant negative form of RhoA downplays the effect of NeuT 
expression on cyclin D promoter activity. On the contrary, inhibition of the PI3K 
pathway has no effect on cyclin D induction by the constitutively active form of ErB2. 
This demonstrates the diversity of signalling activity downstream of growth factor 
activation that converges on cyclin D deregulation and promoting cell cycle progression 
through G1. 
 
1.2.3.4 Ras GTPase signalling in cancer 
 
 The Ras pathway is a commonly deregulated signalling cascade in cancers, and 
research into inhibitors of the Ras pathway is a fast expanding field. Growth factor 
receptors or receptor tyrosine kinases, such as EGFR act as a membrane-docked 
recruitment centre for effector proteins [168]. The phosphorylated tyrosine residues cause 
conformational change which in turn creates docking sites for adaptor proteins such as 
Grb2 and Shc. Nucleotide exchange factors that facilitate the activation of Ras GTPases 
are recruited to these adaptors, creating a platform for activation of Ras. Mutations 
leading to hyper-activation of Ras are common in many cancers [169-172]. These 
mutations impair the intrinsic GTPase activity of Ras and renders the protein resistance to 
GTP hydrolysis, thus maintaining Ras in a constantly active state [173]. The 
constitutively active form of K-Ras (G12D) activates Raf/MEK/ERK signalling pathways 
and lead to tumourigenesis in nude mice [174]. Expression of a hyperactive H-Ras 
mutant (Q61L) in transgenic mice also results in bladder cancer formation accompanied 
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by activation of the Akt pathway [175]. Despite the prevalence of Ras mutations, they are 
not commonly observed in gliomas [4]. It is likely that Ras hyper-activity in gliomas is 
the result of gene amplification and deregulation of upstream events such as increased 
growth factor activation [176]. 
 
 Ras is essential for growth factor-mediated proliferation – over-expression or 
expression of constitutively active mutants of Ras lead to serum-independent DNA 
synthesis, transformation and tumourigenesis in nude mice [177-179]. Ras functions via 
the Raf/MEK/MAPK signalling pathways to activate transcription factors such as c-Jun, 
leading to increased cyclin D expression [180, 181]. Ras also activates the PI3K pathway 
to stabilize cyclin D transcripts. PI3K stabilizes cyclin D protein by preventing its 
phosphorylation and subsequent degradation through glycogen synthase kinase 3β (GSK 
3β), thus maintaining a pool of active Cyclin D-CDK4/6 complexes in the cell [182, 
183]. Phosphorylation by ERK1/2 also activates the ribosomal S6 kinase p90Rsk, 
activating the transcription factor cAMP-response element binding protein (CREB). This 
leads to increased cyclin D expression and facilitates E2F-mediated transcription of S 
phase genes [184-186]. In addition, Ras signalling also promotes cell cycle progression 
through stabilizing the transcription factor c-Myc and increasing Cyclin D1 and Cyclin E 
expression [187-190].  
 
Apart from promoting cell cycle progression through the G1 phase, Ras signalling 
can also contribute to tumourigenesis through inhibition of apoptosis. The 
Raf/MEK/ERK cascade inactivates the anti-apoptotic protein Bad through 
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phosphorylation at S112, leading to sequestration by 14-3-3 chaperone proteins [191]. 
ERK phosphorylation also dissociates Bim, a pro-apoptotic protein from Bcl-2, Bcl-XL 
and Mcl-1. This prevents the homo-dimerisation and activation of the pro-apoptotic 
protein Bax by sequestration to Bcl-2, Bcl-XL and Mcl-1 [192-194]. 
 
1.2.3.5 Rho GTPase signalling in cancer 
 
The Rho family of GTPases is also activated via nucleotide exchange in response 
to growth factors. Rho GTPases regulate the actin cytoskeleton in response to mitogens. 
Generally, RhoA regulates stress fibres and focal adhesions formation, while Rac1 
regulates lamellipodia formation and Cdc42 regulates filopodia formation [195]. Rho 
GTPases also regulate cell polarity, an essential process in cell migration, by promoting 
the stabilization of microtubules and microtubule capture [196-198]. These Rho-mediated 
cellular processes are facilitated by nucleotide exchange factors that cycle the Rho 
GTPases between an active GTP-bound and inactive GDP-bound state.  
 
In recent years, investigations into the mechanisms of Rho-induced 
transformation are fast gaining momentum as more literature demonstrate its role in cell 
cycle progression and tumourigenesis [199-202]. Rho appears to co-operate with Ras in 
cellular transformation and evidence supporting this is highlighted in the following 
studies [203]. Using similar experimental designs, the investigators demonstrate how 
mutations in Rho abolish Ras-induced transformation. Firstly, RhoH over-expression is 
able to induce serum-independent growth in vitro and induce tumourigenesis in nude 
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mice [204]. Constitutively active mutants of Rho mirroring those of Ras activating 
mutations are also expressed, albeit with a lack of transforming potential. Secondly, Ras-
mediated cellular transformation is dependent on RhoB [205]. Expression of a dominant 
negative form of Rho (RhoBV14) attenuates the transforming capability of Ras, although 
expression of the constitutively active Rho mutant alone is insufficient to induce foci 
formation. Also, the introduction of constitutively active RhoA (V14-RhoA) alone into 
mouse fibroblasts does not induce transformation but significantly enhances foci 
formation in the presence of Raf1. The co-expression of dominant negative RhoA (N19-
RhoA) with Ras-V12 abrogates the Ras-transformed phenotype [206]. Lastly, another 
Rho family GTPase Rac is shown to be required for Ras-mediated transformation and 
potentiates Raf-induced transformation in mouse fibroblasts [207]. These results indicate 
that Rho alone does not induce transformation. Rather, it co-operates with Ras signalling 
pathways to result in both morphological and cellular alterations typical of transformed 
cells.  
 
How does Rho co-operate with Ras to induce cellular transformation? Studies into 
the cellular functions of Rho have provided clues. Rho mediates cytoskeletal changes 
such as membrane ruffling and stress fibre formation through modulating actin 
polymerization and bundling of actin filaments in response to mitogens and growth 
factors [208-211]. In Ras-induced transformation, cells undergo morphological changes 
such as loss of stress fibres and increased membrane ruffling [212, 213]. Ridley and 
colleagues show that constitutively active Rac1 (V12Rac1) induces membrane ruffling in 
serum-starved 3T3 cells whereas inactive Rac1 (N17Rac1) inhibits this process in PDGF-
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stimulated fibroblasts. Expression of N17Rac1 also reverses actin polymerization and 
membrane ruffling induced by Ras [211]. Another study also demonstrates the 
requirement for RhoA and Rac1 in maintaining the transformed phenotype in Ras-
transformed fibroblasts. Conversely, dominant negative forms of RhoA and Rac1 inhibit 
Ras-induced foci formation. Consistent with previous findings, the activating mutants of 
RhoA and Rac1 alone are insufficient to induce transformation and need co-operation 
from Ras signalling. Furthermore, MAPK inhibitors attenuate Ras-induced 
transformation. This implicates the MAPK signalling pathway in Ras-mediated 
transformation, although it may not be directly linked to RhoA and Rac1-induced 
cytoskeleton re-organization [214].  
 
Rho signalling is required for cell cycle progression. This is first observed when 
introduction of the C3 inhibitor or inactive form of RhoA inhibit the G1/S progression in 
serum-stimulated fibroblasts [215, 216]. In contrast, G1/S progression is restored when 
active RhoA is introduced into quiescent fibroblasts. Subsequent biochemical studies 
support the function of RhoA in G1/S progression. RhoA also modulates the levels of 
another CDK inhibitor p27Kip1. In one study, geranylgeranylated RhoA were targeted to 
the cytoplasmic membrane and promoted the degradation of p27Kip1. This resulted in 
CDK2 activation followed by G1/S progression [217]. Apart from suppressing CDK 
inhibitors, Rho signalling also induces cyclin transcription and expression. Welsh and 
colleagues demonstrated that RhoA activity is required for sustained activation of cyclin 
D1 expression during G1 [218]. The RhoA effector kinase ROCK also regulates levels of 
cyclin D1 and p27Kip1 expression in mouse fibroblasts [219]. Tanaka et al have shown 
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that geranylgeranylated RhoA promotes the expression of cyclin E in rat astrocytes. The 
consequence is increased CDK2 activation and G1/S progression. Subsequently, it was 
shown that an auto-feedback regulation between p27Kip1 and cyclin E-CDK2 is under the 
stimulation of RhoA signalling. Together, these results demonstrate that degradation of 
p27Kip1 is mediated by cyclin E-CDK2 [220, 221]. This adds a layer of complexity to 
RhoA-mediated G1/S progression. It is not shown though, if the increased CDK 
activation is the result of decreased p27Kip1 inhibition, the increase in cyclin D-CDK4/6 
complexes which sequester p27Kip1 away from cyclin E-CDK2, or the increase in cyclin E 
expression that leads to the formation of more active cyclin E-CDK2 complexes.  
 
These data lead to the question of how the function of RhoA in G1/S progression 
synergizes with Ras signalling in cellular transformation. Two studies have demonstrated 
the co-operation between Ras and Rho signalling in mediating G1/S progression. The first 
study by Olson et al examined how Ras and Rho co-operate to regulate expression of the 
CDK inhibitor p21Cip1 in mouse fibroblasts. When RhoA signalling is inhibited, active 
Ras causes elevation of p21Cip1 levels. This is demonstrated by the induction of p21Cip1 
levels when the RhoA inhibitor C3 is introduced into fibroblasts expressing V12H-Ras. 
Conversely, expression of active RhoA (L63RhoA) abolishes Ras-induced p21Cip1 up-
regulation in serum-starved fibroblasts and stimulates DNA synthesis. These results 
indicate that the main function of RhoA in Ras-mediated transformation is to suppress 
p21Cip1 transcription and expression [222]. The second study revealed a different target of 
RhoA regulation in Ras-induced transformation. RhoA was shown to suppress p27Kip1 
through decreasing its translation efficiency; expression of dominant negative Rho 
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promoting the synthesis of p27Kip1. Furthermore, co-expression of active RhoA and active 
Ras induced transformation in both p16INK4- and Rb-null cells, but not in p27Kip1-null 
cells [223]. This demonstrates that RhoA can also facilitate Ras-mediated transformation 
through p27Kip1.  
 
The relationship between RhoA and Ras in mediating cellular transformation is 
defined and may underpin the role of RhoA in tumourigenesis. However unlike Ras, 
activating mutations of RhoA are rare [224]. Instead, increased levels of RhoA have been 
detected in breast and testicular cancers, and expression correlates with tumour 
progression [225, 226]. The activity of RhoA is dependent to a large extent on its guanine 
nucleotide exchange factor (GEF). It is more likely that deregulated GEF activity, leading 
to increased activation of RhoA, underpins the mechanism of RhoA-mediated 
transformation. 
 
1.3 Guanine nucleotide exchange Factors 
 
In recent years, a lot of interest has been generated in the study of guanine 
exchange factors, their mode of regulation and mechanisms by which they induce cellular 
transformation [227]. This is attributed to their important role in regulating the activity of 
both the Ras and Rho families of GTPases. The exchange factor for Ras, Sos is recruited 
to the plasma membrane through the adaptor protein Grb2. This interaction between Sos 
and Grb2 is essential for the subsequent activation of Ras. Furthermore, both the N- and 
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C-terminus of Sos must be intact in order to mediate growth factor signalling through to 
Ras [228, 229].  
 
The activation of Rho GTPases is dependent on the Dbl family of guanine 
nucleotide exchange factors and is a structurally different family from Ras GEFs. Similar 
to Ras GEFs, the exchange factor first forms a complex with GDP-bound RhoGTPase 
before releasing GDP. GTP immediately replaces GDP due to the high intracellular ratio 
of free GTP/GDP [230]. GEFs facilitate the activation of Rho GTPase-mediated changes 
in cellular processes such as actin cytoskeleton reorganization, adhesion and migration, 
polarization, phagocytosis and cell growth and proliferation [231-234].  
 
1.3.1 Structure and function of the Dbl proteins 
 
 The Dbl protein was isolated as a transforming gene from human diffuse B cell 
lymphoma [235]. Its oncogenic potential is activated through N-terminal truncation. Dbl 
shares significant sequence similarity with the yeast Cdc24 protein and this region of 
sequence homology is designated as the Dbl homology (DH) domain [236-238]. Based 
on genetic studies, Cdc24 lies upstream of Cdc42, a Rho GTPase required for bud site 
assembly [239].  Since Cdc24 and Dbl exhibit a great degree of sequence similarity, it is 
possible that Dbl can catalyse guanine nucleotide exchange on human Cdc42 GTPase as 
well. Hart et al demonstrated that the Dbl protein is capable of facilitating nucleotide 
exchange on Cdc42 GTPase and provides the impetus for further investigation into the 




 Subsequently, more members of the Dbl family of proteins were identified via 
sequence homology at the DH domain. Several were isolated from screens for the ability 
to transform mouse fibroblasts in vitro, such as Lbc, Lsc and Lfc [236, 238, 241]. Many 
have expanded repertoires of substrates, which extend to RhoA and Rac1 GTPases as 
well. In addition to the DH domain, all Dbl family proteins contain a second domain 
known as pleckstrin homology (PH) domain. These two modules are always found in 
tandem, and there is little similarity between the Dbl family members apart from the DH 
and PH domains.  
 
1.3.1.1 The DH Domain 
 
 The structure of the DH domain and the manner that it interacts with its Rho 
substrates underpins the mechanism for the nucleotide exchange activity of Dbl proteins. 
X-ray crystallography studies have determined the structure of Rac1 in complex with the 
DH/PH catalytic domain of Tiam1 and have advanced understanding in this area [242]. 
The DH domain is defined by three regions of primary sequence known as CR-1, CR-2 
and CR-3. These regions also represent a surface essential for the exchange factor’s 
molecular interactions, as mutations in this conserved region disrupt the exchange 
factor’s catalytic activity. For instance, point mutation of a highly conserved glutamic 
acid residue in the DH domain of the Trio GEF greatly attenuates nucleotide exchange 
[243]. Trio is the first GEF characterized and contains two catalytic domains directed 
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against two different GTPase substrates, Rac1 and RhoA [244, 245]. As based on 
crystallography studies, the general nucleotide exchange mechanism involves disruption 
of the Mg2+ ion-binding site and the P-loop of Rac1 by the GEF Tiam1. These two 
surfaces maintain contact with the nucleotide, and disruption results in destabilization of 
the GTPase with the β-phosphate of the nucleotide [242, 246, 247].  
 
1.3.1.2 The PH Domain 
 
 The PH domain is invariably found on the C-terminus end of the DH domain, and 
these two domains function together to activate Rho GTPases [248, 249]. It is believed 
that PH domains facilitate targeting of the exchange factor to the cytoplasmic membrane, 
since they are able to bind to the βγ subunits of G proteins and acidic phospholipids [250-
252]. Disruption of membrane localization of the exchange factor greatly reduces its 
nucleotide exchange efficiency. Liu et al demonstrated that when the PH domain of the 
Trio exchange factor is removed, the rate of GDP release on Rac1 GTPase is significantly 
lower compared to that with an intact DH/PH domain [243]. Whitehead et al further 
illustrate the biological importance of the PH domain and membrane targeting of the 
exchange factor by removing the PH domain of the exchange factor Lfc. The 
transforming potential of Lfc in mouse fibroblasts is significantly attenuated but was 
readily reversed with the addition of an iso-prenylation site [253]. Despite the consensus 
that PH domains mediate membrane targeting, Dbl with its PH domain replaced by a 
Ras-derived membrane targeting sequence is unable to reverse the inability of Dbl-PH 
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mutants to transform mouse fibroblasts, suggesting that the PH domain may also mediate 
interaction with other components in the cytoplasm for Dbl to function [254]. It is further 
shown that the PH domain of another GEF, Trio associates with cytoskeletal structures, 
indicating that the targeting specificity of PH domain may vary with the location of its 
exchange factor [255]. 
 
1.3.2 Dbl proteins in cancer 
 
 Almost all of the members of the Dbl family of exchange factors were isolated 
from genetic screens for transforming potential in mouse fibroblasts. All are bona fide 
exchange factors that are activated oncogenes when truncated; however this is most likely 
due to experimental manipulation rather than reflecting the actual in vivo situation. In 
fact, only a small number of Dbl exchange factors that are mutated in cancers have been 
reported, and their mechanisms of inducing transformation remain unclear. 
 
 One example of this is the Bcr gene. The Bcr-Abl fusion is a commonly found 
mutation in patients with chronic myelogenous leukemia. It is a result of the Philadelphia 
chromosome, a translocation event resulting in the exchange of genetic material between 
region q34 of chromosome 9 and region q11 of chromosome 22 [256-258]. Bcr contains 
sequence homology to Dbl and is shown to catalyse GTP binding to cdc42, RhoA and 
Rac1 [259]. At the same time, the Bcr-Abl fusion gene products contain constitutively 
activated Abl tyrosine kinase activity, which contributes to tumourigenesis [260]. 
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However, it is still unclear how the DH domain of Bcr mediates oncogenesis in the 
context of the Bcr-Abl gene. Some studies reveal that the DH domain in Bcr-Abl is a 
biologically functional module. When Bcr-Abl DH domain is replaced with either other 
homologous sequences from Dbl or unrelated sequences from the LacZ or luciferase 
genes, the transforming potential of these mutants is significantly attenuated [261]. 
Furthermore, Rac1 activity is shown to increase in myeloid precursor cells ectopically 
expressing p210-Bcr-Abl, implying a role for Bcr exchange activity in oncogenesis [262]. 
 
 Another example of Dbl proteins with no activating mutations but involved in 
tumourigenesis is Vav1. Vav1 is an exchange factor expressed in cells derived from the 
bone marrow lineage and catalyses nucleotide exchange on the Rho family of GTPases 
[263, 264]. It is regulated by phosphorylation mediated by both receptor tyrosine kinases 
as well as non-receptor kinases. While truncated forms of Vav1 are able to induce 
transformation in mouse fibroblasts, it is expressed as a full-length functional protein in 
pancreatic cancer [265, 266]. Furthermore, Zapico and colleagues demonstrate that the 
ectopic expression of Vav1 correlates with decreased survival. In addition, Vav1 down-
regulation results in the decrease of EGF-stimulated JNK activation, indicating that Vav1 
may be required for activating cell proliferation pathways downstream of growth factor 
receptors. More importantly, a direct role for Vav1 in cell cycle progression is implied as 
Vav1 over-expression results in increased cyclin D1 promoter activity in the same 
pancreatic cancer cell line. These events are dependent on the exchange activity of Vav1 
[266]. Since Rho GTPases regulate many signalling events promoting cell cycle 
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progression, it is not surprising that over-expression of their exchange factors can lead to 




















































Figure 1.4. Simplified scheme of Ras and Rho signalling events cumulating in 
cellular transformation and tumourigenesis. Ras and Rho act as molecular switches in 
response to growth factors. Activation of the GTPases is determined by the guanine 
exchange factors (GEF) and deactivated by the GTPase activating proteins (GAP). GEFs 
highlighted are possible regulators of GTPase activity in transformation. Current 
literature has not fully delineated the hierarchy of Raf/MEK/MAPK signalling with 
respect to Rho although there is suggestion that it exists as a parallel pathway. Asterisks 
denote frequency with which each event occurs in human cancers; more asterisks indicate 
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CHAPTER 2: INTRODUCTION 
 
2.1  Isolation of the Ect2 proto-oncogene 
 
 The Ect2 (Epithelial Cell Transforming Sequence 2) protein was first isolated in a 
screen for cDNA capable of inducing transformation in mouse fibroblasts. The isolated 
cDNA induced colonies at a high efficiency and formed palpable tumours in nude mice 
[267]. Analysis revealed that transforming potential was activated by oncogenic 
truncation of the N-terminal domains. Ect2 has two tandem repeats of the BRCA1-related 
BRCT domains as well as the DH and PH domains on the C-terminus (Figure 2.1). The 
BRCT domains share homology with proteins such as BRCA1, Rad9, Cut5/Rad, which 
are implicated in DNA damage responses (Figure 2.2). Sequence comparison also 
showed that Ect2 shares significant similarities with the Bcr, dbl oncogenes and with the 
yeast CDC24 protein, all of which are nucleotide exchange factors regulating the activity 
of Rho GTPases (Figure 2.3). 
 
2.2 Cell-cycle dependent regulation of Ect2 
 
 
 The cellular localization of Ect2 varies with cell cycle progression [268]. During 
interphase, Ect2 is sequestered in the nucleus, only to be released and re-distributed 
throughout the cytoplasm following nuclear membrane break down. During mitosis, Ect2 

















Figure 2.1 Structure of Ect2 gene. Ect2 contains a putative central nuclear localization 
signal (NLS), which is essential for proper compartmenting of the protein. The two 
tandem BRCT repeats on the N-terminus inhibit the C-terminus DH and PH domains, and 
regulate the nucleotide exchange activity of Ect2. Loss of the central NLS and the two 

























Figure 2.2 Alignment of Ect2 BRCT domains with other BRCT-containing proteins. The BRCT domains of Ect2 share 
significant similarity with those of the tumour suppressors BRCA1, as well as with the yeast Cut5/Rad4. Among these various BRCT 
proteins, some have multiple BRCT repeats, while others have additional functional domains. For instance, DNA ligase IV contains a 




























Figure 2.3 Alignment of Ect2 with other Dbl proteins. Ect2 is identified as a member of the Dbl family of proteins based on its DH 
and PH domains. These two domains often exist in tandem, and are believed to co-operate to confer specificity of substrates and 
localization in order for the exchange factor to activate its Rho GTPases. Members such as Vav have an additional SH3 domain to 
facilitate substrate targeting and Bcr has kinase and GAP activities on top of its predicted nucleotide exchange activity, while Tiam 















furrow during cytokinesis. Since expression of dominant negative mutants of Ect2 
(lacking the DH/PH domains) give rise to multi-nucleated cells, the protein is implicated 
in RhoA-mediated cytoskeletal changes required for cytokinesis. Ect2 expression is 
induced by keratinocyte growth factor (KGF) and epidermal growth factor (EGF) in 
serum-starved mouse epidermal keratinocytes [269]. Protein levels are low during G1 and 
gradually increase at the G1/S border before finally peaking at G2/M. Phosphorylation and 
activation of Ect2 follows a similar trend, with maximal phosphorylation at G2/M [270]. 
The phosphorylation at Thr341 by cyclin B-CDK1 does not alter the cellular localization 
of Ect2 and rescues cytokinesis defects arising from down-regulation of Ect2 using 
siRNA, indicating biological activity of the phosphorylated protein. Expression of both 
phospho-mimic and phospho-deficient Ect2 mutants demonstrate that phosphorylation is 
not required for Ect2 exchange activity. However, phosphorylation of Thr341 induces 
conformation change in Ect2, causing the N-terminal inhibitory BRCT domains to 
dissociate from the C-terminus, and thus enhancing catalytic exchange activity, [270, 
271]. 
 
2.3  N-terminal domains of Ect2 are similar to cell cycle regulatory 
 proteins 
 
The N-terminal domains of Ect2 are related to the BRCA1 gene product. The 
BRCT domains are found in DNA repair and DNA damage response proteins, and play 
an important role in mediating protein interactions upon DNA damage [272, 273]. The 
functions of BRCT proteins are multi-faceted. For instance, the BRCT domains of 
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XRCC1 facilitates the interaction between PARP-1 and DNA Ligase I during single 
strand break repair or BER, while the BRCT domains of NBS1 co-operate with its 
forkhead-associated domain (FHA) and regulate binding of NBS1 to H2AX. This 
facilitates targeting of the MRN complex to the sites of double strand breaks [274]. 
BRCT domains of BRCA1, TopBP1 and XRCC1 also bind DNA breaks directly, with 
BRCA1 and TopBP1 also exhibiting transcriptional regulation activities [275-278].  
 
The BRCT domains of Ect2 are able to recognize and bind to a phospho-peptide 
motif generated by ATM/ATR phosphorylation in response to DNA damage [279]. Ect2 
BRCT also shares significant homology with the yeast Cut5 protein, which is implicated 
in DNA damage checkpoint and DNA replication [280, 281]. Despite these similarities, it 
is not known if the BRCT domains of Ect2 share similar characteristics as other BRCT 
proteins.  
 
2.4 Cellular functions of Ect2 
 
Ect2 is a unique protein with a RhoGEF domain and two tandem BRCT repeats. 
To date, Ect2 is well-characterized for its role in cytokinesis and cellular transformation, 
although recent investigations are uncovering new roles for Ect2 in establishing cell 
polarity and cell cycle progression as well. This section reviews the studies that provided 
the evidence for each function of this protein. 
 




The role of Ect2 in cytokinesis is the most well-defined function of this protein. 
Ect2 is a RhoGEF specific for RhoA GTPases. Rho GTPases are involved in a plethora of 
cellular processes such as cytoskeletal remodelling, cell motility, transcription and cell 
cycle progression [203]. Evidence supporting a role for Ect2 in cytokinesis is highlighted 
in the following experiments.  
 
The first suggestion of Ect2 being involved in cytokinesis came from an a 
demonstration showing that Ect2 participates in cytokinesis through its RhoGEF domain 
and catalyzes nucleotide exchange on RhoA, Rac1 and cdc42 [268].  The localization of 
Ect2 at the midzone during cytokinesis strongly implied a role for Ect2 in cleavage 
furrow formation. Furthermore, expression of dominant negative Ect2 (lacking the DH 
and PH domains) or micro-injection of anti-Ect2 antibodies resulted in the formation of 
multi-nucleated cells, indicating cytokinesis failure. These results lay the foundation for 
subsequent studies into how Ect2 is involved in cytokinesis through its Rho substrates. 
Secondly, activation of RhoA by Ect2 is required for cytokinesis, thus identifying the 
specific substrate for Ect2 in this function [282]. The expression of dominant negative 
Ect2 reduces RhoA activation during telophase, resulting again in cytokinesis failure. 
Apart from RhoA, cdc42 is also a substrate of Ect2 required for spindle assembly [283]. 
Inhibition of Xenopus Ect2 with neutralizing antibodies prevented the formation of 
spindle fibres during mitosis. In addition, expression of dominant negative cdc42 resulted 
in a phenotype similar to inhibition of Ect2. Thus it is likely that Ect2 promotes the 




 To examine how Ect2 participates in cytokinesis in mammalian cells, other 
binding partners of Ect2 must be identified. Clues are drawn from studies carried out with 
Pbl, the Drosophila homologue of Ect2. Pbl forms a trimeric complex with MgcRacGAP 
and Pavarotti at the contractile ring during cytokinesis [284]. MgcRacGAP is an 
evolutionarily conserved GTPase activating protein (GAP) that inactivates RhoA while 
Pavarotti is a mitotic kinesin [285, 286]. These two proteins form the micro-tubule 
bundling complex centralspindlin, which is required for the formation of the central 
spindles during mitosis [287, 288]. Based on these findings, a model for the positioning 
of the contractile ring during cytokinesis was proposed, whereby Pavarotti and 
MgcRacGAP targeted to the equatorial ring through the microtubules. This is likely since 
microtubules rearrange themselves to form a bundled structure known as the central 
spindlin involving Pavarotti, which evolves to become the midbody [289]. Through 
interaction with MgcRacGAP, Pbl is activated leading to activation of RhoA and 
ultimately formation of the contractile ring [290]. Remarkably, MgcRacGAP interacts 
with Pbl through the N-terminus BRCT domains [284]. Although this observation 
demonstrated the mediation of protein-protein interactions through BRCT domains, the 
context in which it exists is atypical of BCRT proteins, which are generally involved in 
DNA damage responses [272, 273].  A later study demonstrated a similar interaction 
between MgcRacGAP and Ect2 and that this interaction is necessary for targeting of Ect2 
to the central spindle and subsequent contractile ring formation in HeLa cells [291]. The 
interaction between Ect2 BRCT domains and MgcRacGAP in mammals was confirmed 
in HeLa cells [292]. Finally, it was shown that RhoA is targeted to the cortical region by 
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Ect2 and the central spindling complex, resulting in cleavage furrow formation in HeLa 
cells [293]. These results indicate that the role of Ect2 in cytokinesis is evolutionarily 
conserved and requires all domains of the protein to be intact.  
 
2.4.2 Ect2 induces cellular transformation 
 
 As opposed to the function of Ect2 in cytokinesis, arriving at the conclusion that 
Ect2 induces cellular transformation is much more straightforward considering that the 
protein is isolated from a screen for cDNAs capable of transforming 3T3 mouse 
fibroblasts. That Ect2 shares homology with the Dbl family of oncogenes and in vivo 
models demonstrate the tumourigenic effect of activated Ect2 further support a role for 
Ect2 in neoplastic development [267, 294]. Given the direct implication in oncogenesis, 
elucidating the mechanism by which Ect2 induces transformation is of great significance.  
  
 Several in vitro investigations were carried out to propose a mechanism for Ect2-
mediated transformation. The transforming potential of Dbl oncogenes corresponded with 
their ability to induce cyclin D1 promoter activity, suggesting a possible role for Ect2 in 
promoting cell proliferation [295].  This was supported by the findings that Ect2 is highly 
expressed in a mouse liver regenerating model where liver cells divide rapidly following 
hepatectomy [296]. Ect2 expression is also induced by growth factors, and that Ect2 
mRNA is highly expressed in several human cancer cell lines [269]. This suggests that 
Ect2-mediated transformation is linked to its role in proliferation. Studies were also 
carried out to examine the molecular aspects of Ect2-mediated cellular transformation. 
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The Ect2 N-terminal BRCT domains interact intra-molecularly with the C-terminus 
DH/PH domains, resulting in auto-inhibition of Ect2 RhoGEF activity. This provided a 
possible explanation of how N-terminal truncation of Ect2 could lead to transformation 
and tumourigenesis [271]. Further studies showed that despite the loss of inhibition on 
the C-terminus RhoGEF activity, it is the loss of a nuclear localization signal leading to 
cytoplasmic mislocalization of Ect2 that precipitates cellular transformation. The same 
report also implicates RhoA signalling pathways in Ect2-mediated transformation, 
although the exact effector pathways leading to the observed phenotypes are not 
uncovered [297]. In addition, the C-terminal sequences next to the DH/PH domain of 
Ect2 confers substrate specificity to Ect2 exchange activity and determine the 
transformed phenotype. BRCT-truncated only Ect2 can catalyse exchange on RhoA, 
Rac1 and cdc42 whereas Ect2 without the C-terminus sequences only recognizes RhoA. 
This gives rise to the different transformed morphology observed [298]. 
 
 Besides in vitro studies, there are also several lines of evidence from in vivo 
studies that implicate Ect2 in transformation and tumourigenesis. Differential gene 
display analysis of mouse embryonic cells transformed by carcinogenic nickel oxide 
reveals the over-expression of Ect2 mRNA in transformed cell lines. The same group 
followed up on these results and showed that expression of full-length Ect2 in these 
transformed cell lines had increased by 3 to 4.5-fold. This also corresponded to the 
amplification of Ect2 gene observed [299, 300]. An in vivo model of ductal carcinoma 
progression in mice was used to investigate the molecular changes associated with 
different stages of malignancy in breast cancers. It found that Ect2 cDNA was amplified 
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in the premalignant lesions but not in the normal fat pads of genetically engineered mice, 
indicating that Ect2 over-expression may be one of the molecular events associated with 
malignancy [301].  
 
 Lastly, a genome-wide profiling of chromosomal aberrations in brain tumours 
revealed that 30% of the GBM primary cell lines tested showed amplification of 
chromosome 3q26 where the Ect2 gene is mapped to. This was verified later in patient 
tissue samples. Over-expression of the full-length Ect2 mRNA and protein correlated 
with increased tumour grading, invasiveness and inversely correlates with patient survival 
[302]. Surprisingly, amplification of 3q26 in squamous cell carcinoma did not show a 
corresponding amplification of the Ect2 gene or any correlation between Ect2 
amplification and tumour grading [303]. This suggested that this relationship between 
Ect2 expression, tumour grade and patient prognosis is unique to gliomas. 
 
 Review of the existing literature revealed two interesting aspects of Ect2-
mediated transformation and tumourigenesis. Firstly, the in vitro molecular experiments 
show that exogenous expression of the full-length Ect2 protein displays almost no 
transforming potential while the exogenous expression of the N-terminal truncated form 
(lacking the central nuclear localization signal) has the strongest transforming potential. 
In contrary, animal carcinogenesis models have increase in the full-length transcripts and 
Ect2 is expressed as an intact full-length protein in patient samples. Herein lies the 
contradiction between in vitro experiments and in vivo observations, which has not been 
adequately addressed in the current body of literature. Secondly, cleavage furrow 
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formation during cytokinesis is clearly an important physiological function of Ect2. 
However, there is no indication of how this function of Ect2 can contribute to its role in 
transformation and tumourigenesis. Therefore, other function of Ect2, perhaps related to 
cell cycle progression, may be more relevant to its capability to transform cells in vitro 
and its observed correlation to tumour grading and patient prognosis. Consistent with this 
notion, the C. elegans orthologue of Ect2 is able to activate the Ras/MAPK pathway 
before S phase during vulval cell fate determination [304]. Epistasis studies further 
demonstrate that Ect2 may interact with the Ras/MAPK pathway through Rho signalling. 
This provides a possible link between Ect2 transformation and the Ras signalling 
pathway. Furthermore, a possible role for Ect2 in the G1/S transition was recently 
demonstrated, although it was defined in a different context [305]. Thus, investigations to 
delineate the specific signalling and downstream pathways modulated by Ect2 during 
transformation and oncogenesis are of great importance.  
 
2.4.3 Regulation of epithelial cell polarity and migration by Ect2 
 
 The role of Ect2 in maintaining cell polarity is a recently-uncovered function. A 
handful of literature has defined the binding partners of Ect2 and possible mechanism by 
which Ect2 regulates epithelial cell polarity and migration using different biological 
models. Accurate determination of cellular polarity is essential for various cellular 
processes, including asymmetrical cell division, directional cell migration, and 
establishment and maintenance of apical-basal polarity in epithelial cells [306-308]. Rho 
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GTPases participate in these processes, suggesting their guanine exchange factors are 
also able to regulate these events.  
 
 Ect2 is identified as one of the GEFs interacting with the polarity determinant 
Par6 based on yeast two-hybrid analysis [309]. Par6 also binds to atypical protein kinase 
C (aPKCζ) and another polarity determinant Par3. Together they regulate tight junction 
formation in canine kidney cells [310-312]. Tight junctions are essential structures for 
establishing and maintenance of epithelial polarity of the cell membrane [313].  
Subsequently, Ect2 was found to localize at the tight junctions in a calcium-dependent 
manner. In addition, Ect2 is able to regulate the activity of aPKCζ, thus suggesting a role 
for Ect2 in tight junction formation [309] Liu et al further demonstrated that Ect2 
regulates epithelial cell polarity by showing that dominant negative Ect2 is unable to 
induce central lumen formation in canine kidney cysts in 3D collagen gels. Lumen 
formation in these cysts is mediated through selective apoptosis [314, 315]. This is 
disrupted by expression of dominant negative Ect2 and subsequently establishment of 
epithelial cell polarity. This eventually results in inhibition of apoptosis in specific cells 
at the centre of the lumen, and the failure to form cysts.  
 
 At the same time, Ect2-mediated cell migration was demonstrated in C. elegans. 
The RhoGEF activity of Ect2 is required for the migration of ventral hypodermal blast 
cells (P cell). Typically, P cells are present upon hatching and subsequently migrate to the 
ventral midline during the larvae stage. Following which, each P cell divides along the 
anterior–posterior axis to produce two daughter cells. The ventral migration of P cells is 
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inhibited in Ect2-negative worms, indicating that Ect2 is required for this event. This 
observation is also consistent with previous reports demonstrating that the Drosophila 
orthologue of Ect2, Pbl, is essential for mesodermal cell migration during embryogenesis 
[316, 317]. Taken together, these results indicate an important role for Ect2 in cell 
migration as well as in development. 
 
2.5 Scope of this study 
 
Firstly, although studies by other groups have shown that Ect2 is required for 
transformation and the G1/S transition in a p53-dependent manner, the exact mechanism 
and pathways implicated are not known. Also, the current approach of using ectopic 
expression of truncated Ect2 is not physiological since only the full-length protein is 
detected in patient samples. Secondly, while the investigations of Sano et al and Yang et 
al demonstrate that the correlation between full-length Ect2 expression and tumour 
grading is an observation unique to gliomas only, the question of how full-length Ect2 
over-expression is biologically relevant to glioma progression is not clearly addressed 
[302, 303].  
 
In this study, we first hypothesize that over-expression of full-length Ect2 has 
biological consequences in human glioma cells in vitro, specifically that of promoting the 
G1/S transition through enhancing RhoA GTPase activity. Since RhoA regulates the G1/S 
transition by modulating the p27Kip1 CDK inhibitor, we propose that Ect2 acts on cell 
cycle progression via the same pathway [220, 318].  Secondly, we investigate the 
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functional relationship between Ect2 over-expression and glioma progression in vitro by 
examining the need for Ect2 in glioma viability and invasion. Lastly, we propose that the 
growth-promoting effect of Ect2 may be targeted as an alternative strategy in the 
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1  Reagents and chemicals 
 
 Horseradish peroxidase-conjugated donkey anti-mouse and goat anti-rabbit 
antibodies were purchased from Pierce (Rockford, IL) and Santa Cruz (Delaware, CA) 
respectively. Chemiluminescent detection system was supplied from Amersham 
Pharmacia Biotech (Arlington Heights, IL). High glucose Dulbecco’s Modified Eagle 
Medium (hi-Glu-DME) and penicillin-streptomycin were from Invitrogen (Carlsbad, 
CA). Foetal bovine serum was purchased from Hyclone (South Logan, UT). MG132 was 
obtained from Calbiochem (San Diego, CA). Actinomycin D was purchased from Sigma 
(St. Louis, MO). SilentFect and PolyFect reagents were purchased from Bio-Rad 
(Hercules, CA) and Qiagen (Hilden, Germany) respectively. siRNAs were synthesized by 
Dharmacon (Lafayette, CO). Ect2 siRNA sequences used were from Kamijo et al and 
Scoumanne and Xu [305, 319].  
 
3.2 Plasmids and constructs 
 
 Ect2 (containing BamHI and EcoRI restriction sites) was cloned into pGEM-T 
using TA cloning (Promega, Madison, WI). The full-length construct was subsequently 
cloned into the mammalian expression plasmid pXJ41 [320]. The following Ect2 
truncation constructs were kind gifts of Der CJ: ∆N-Ect2-DH/PH/C, ∆N-Ect2-DH/PH 
and ∆N-Ect2-DH cloned into pCTV3-HA3 [295, 298]. 




3.3 Cell culture and treatment 
 
 Human glioma cell lines U87-MG, U118-MG and T98G were obtained from 
American Type Culture Collection (ATCC, Manassas, VA) and cultured in DME 
supplemented with 10% FBS,  non-essential amino acids, sodium pyruvate and 
antibiotics in a humidified CO2 incubator at 37 °C. To synchronize U118MG at G0, cells 
were washed three times with saline buffer and switched to serum-free DME for 72 hr. In 
the case of siRNA transfection in synchronized cells, U118MG were starved for 24 hr 
before transfection with 20 nM siRNA using SilentFect reagent. Cells were incubated 
with serum-free DME for an additional 48 hr following siRNA transfection. For siRNA 
transfection in non-synchronized cells, the same procedure was carried out except for the 
presence of serum. To over-express full-length Ect2 and truncated mutants, cells were 
transfected with 1 ug of cDNA constructs using PolyFect reagent for at least 6 hr.  In the 
case of over-expressing Ect2 under serum-free conditions, cells were starved for 24 hr 
before transfection and incubated with serum-free DME for an additional 48 hr following 
the procedure. 
 
3.4 Reverse Transcription and RealTime PCR  
 
First strand cDNA was synthesized using ImPromII Reverse Transcriptase 
(Promega) from 500 ng of total RNA. Real-time PCR was carried out on the DNA 
Engine Opticon (Bio-Rad) in Quantitect SYBR Green Master Mix (Qiagen) in a final 
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volume of 20 µl, containing 3 pmole of each forward and reverse primers. The reactions 
were cycled according to the following parameters: pre-denaturation at 95°C for 15 min 
followed by 40 to 50 cycles (depending on template abundance) of a denaturation step at 
95 °C for 20 sec, annealing step at 50 to 60 °C according to the Tm of individual primers, 
extension step at 72 °C for 30 sec. This was followed by plate reading at 75 °C for 1 sec. 
Melting curve was performed from 65 °C to 90 °C (read every 1 °C; held for 2 sec 
between reads). GAPDH and β-actin were used as internal controls. Differential gene 
expression, expressed as fold changes (2-∆∆CT), and standard deviations (n=3) were 
calculated based on the Comparative CT method [321].  
 
3.5 FACS analysis of DNA content 
 
Cell pellets were collected following treatment and fixed in 70% ethanol at –20 
°C. Cells were then rehydrated with PBS and stained with 10 µg/ml of propidium iodide 
and 100 µg/ml of RNaseA (Sigma). For analysis of DNA synthesis, cells were pulsed 
with 10 µM BrdU (BD Pharmigen) for the indicated durations prior to collection and 
fixed in 70% ethanol at –20 °C. Cells were then rehydrated with PBS and denatured with 
2N HCl with agitation at 37 °C for 30 min. Cells were washed with PBS and immuno-
labelled with FITC-conjugated anti-BrdU antibody (BD Pharmigen). Cells were 
resuspended in 10 µg/ml of propidium iodide and 100 µg/ml of RNaseA and analysed on 
the FACS Calibur (BD Biosciences) using the CellQuest Pro analysis software.  
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3.6 Western blot analysis 
 
Cells were lysed in 0.1% SDS lysis buffer (50 mM Tris-HCl pH7.5, 150 mM 
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1 mM sodium vanadate, 50 mM β-
glycerophosphate, 1 mM NaF) supplemented with protease inhibitor cocktail (Roche, 
Basel, Switzerland). 50 µg of proteins were resolved on 6 to 12% SDS-polyacrylamide 
gels and transferred onto PVDF membranes (Millipore, Billerica, MA). Membranes were 
blocked in 5% skim milk and probed using antibodies specific to p27Kip1 (BD 
Pharmigen), p21Cip1, RhoA, MEK1, Ect2 and RhoA (Santa Cruz), HA (Covance Inc, 
Princeton, NJ), Histone H3 (Upstate Biotech, Billerica, MA) and Rb (Neomarkers, 
Fremont, CA) at a dilution of 1:1000. This was followed by incubation with the 
corresponding secondary antibodies for 1 hr with agitation. Immunoreactive bands were 
visualised by chemiluminescence according to the manufacturer’s directions. 
 
3.7 Chromatin fractionation assay  
 
Chromatin fractionation assay was performed as previously described [322]. 
Briefly, cells were lysed in hypotonic buffer A (10 mM Hepes pH 7.9, 10 mM KCl, 1.5 
mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 0.1% Triton-X supplemented 
with protease inhibitors) and incubated on ice for 5 min. Nuclei were pelleted (P1) by 
centrifugation at low speed (5 min, 1300 g, 4 °C). The supernatant (S1) was further 
clarified by centrifugation at high speed (30 min, 16000 g, 4 °C) to obtain the soluble 
cytoplasmic fraction (S2). To isolate chromatin-bound fractions, P1 was washed with 
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buffer A and resuspended in a low salt buffer B containing 3 mM EDTA, 0.2 mM EGTA, 
1 mM DTT and supplemented with protease inhibitors, followed by incubation on ice for 
30 min. To obtain the insoluble nuclear fraction (P2), the lysate was clarified by 
centrifugation (5 min, 1700 g, 4 °C). The supernatant was retained as the soluble nuclear 
fraction (S3). To obtain the final chromatin-bound proteins, P2 was washed once and 
clarified (5 min, 1700 g, 4 °C). The final pellet (P3) was resuspended in 1 x SDS sample 
buffer and sonicated for 5 sec in a Misonix cell disruptor at 25% amplitude (Misonix Inc, 
Farmingdale, NY). To release chromatin-bound proteins, P3 was resuspended in buffer A 
supplemented with 1 mM CaCl2 in the absence of Triton-X and digested with 0.2 U of 
microccocal nuclease (Sigma). The reaction was stopped by addition of 1 mM EGTA. 
Nuclei were collected by centrifugation and lysed according to the above protocol.  
 
3.8 Cell viability assay 
 
Cell proliferation was measured with 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) colorimetric assay (Sigma). Briefly, cells were 
seeded in 48-well plates and transfected with siRNA the next day. 10 µg/ml MTT was 
diluted 1:4 with medium and added to cells washed with PBS and allowed to incubate for 
1 hr at 37°C. Equivolumes of MTT lysis buffer (50% dimethyl-formamide and 20% 
SDS) were added to solubilise the formazan formed during metabolism. Relative light 
absorbance at 595 nm was measured using an ELISA plate reader (Dynex Technologies, 
Chantilily, VA). To measure long-term viability, cells were seeded in 24-well plates and 
transfected with siRNA the next day. After 24 h, cells were trypsinized and replated at a 
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density of 500 cells/well in 6-well plates and allowed for foci formation over 10 days. 
Colonies were fixed with 4% paraformaldehyde (Sigma) and stained with 1% crystal 
violet (Sigma). Representative fields from each well were counted for number of 
colonies. Student’s t-test was used to calculate statistical significance. 
 
3.9 Rho activity assay 
 
 Rho activation was measured using the Rho Activation Assay Kit (Upstate 
Biotech, Billerica, MA) according to manufacturer’s protocol. Briefly, cells were lysed in 
1 x Mg2+-containing lysis buffer and clarified by centrifugation at 13,000 rpm for 20 min 
at 4 °C. 3 – 500 µg of lysate was incubated with 20 µg of the Rhotekin RBD agarose 
beads and rotated for 1 hr at 4 °C. Beads were washed three times with lysis buffer, and 
released by boiling in 1x SDS sample loading dye supplemented with 10 nM DTT. RhoA 




3.10 mRNA stability and half-life 
 
Cells were treated with Actinomycin D (2.5µg/ml) and total RNA was harvested 
at the time points indicated. Abundance of p27Kip1 transcripts were determined by Real-
time PCR and normalized against actin mRNA.  
 
3.11 Cell invasion assay 




 Glioma cells were starved for at least 24h before seeding at a density of 50,000 
cells/well in a Matrigel-coated Boyden chamber (BD Biosciences) and incubated with 
serum-supplemented DMEM in the lower chamber. Cells were allowed to migrate over 
18h. The following day, the remaining cells and Matrigel were scraped from the upper 
chamber and the migrated cells fixed in 4% paraformaldehyde and stained with 1% 
crystal violet. 10 representative fields were counted under the microscope and paired 
Student’s t-test was used to determine statistical significance.  
 
3.12 Dual-luciferase reporter assay 
 
 Renilla luciferase control plasmid pRL-TK (Promega) was co-transfected with 
firefly luciferase reporter plasmid containing full-length, truncated p27 promoter or 
empty vector at a ratio of 1:20. Renilla and firefly luciferase activity was measured using 
the Dual Luciferase Assay Kit (Promega) according to manufacturer’s protocol. Relative 
luciferase activity was obtained as a ratio of firefly:Renilla activity. Data obtained was 
subsequently normalized against the background from the empty vector.  
 
3.13 Tritiated thymidine ([3H]TdR)  incorporation 
 
The rate of DNA synthesis in human glioma cells was measured as previously 
described [323]. Briefly, cells were seeded in triplicates at 60% confluency and labelled 
overnight with [3H]TdR (Amersham, Arlington Heights, IL). This was followed by 
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incubation with 10% trichloroacetic acid for 10 min and 1 M NaOH for 1 hr.  




CHAPTER 4: RESULTS 
 
4.1  The role of full-length Ect2 in cell cycle regulation 
 
 In this study, we hypothesize a function for full-length Ect2 in promoting cell 
cycle progression. To show that Ect2 is required for the G1/S transition, both mixed 
population and synchronized human glioma cells in quiescence using serum deprivation 
were used to test the effects of over-expression or suppression of Ect2 on cell cycle entry. 
At the same time, the requirement for RhoA activity in Ect2-mediated cell cycle 
regulation was investigated. Since RhoA itself is capable of promoting cell cycle 
progression through modulating the p27Kip1 CDK inhibitor, the ability of Ect2 to exert the 
same influence on p27Kip1 was also examined.  
 
4.1.1 Ect2 suppression-induced G1 arrest leads to decreased DNA synthesis 
 
 To investigate the requirement for Ect2 in G1 progression, asynchronous human 
glioma cells U87MG, U118MG and T98G were transfected with Ect2 siRNA K and 
analysed 24h later [319]. In control or scrambled sequence siRNA- transfected cells, the 
percentage of cells in G1 was 55% and 53% respectively. In Ect2 siRNA-transfected 


























Figure 4.1 Down-regulation of Ect2 is accompanied by accumulation in G1. (a) 
Immunoblot showing the efficiency of silencing using siRNA. (b) FACS histogram 
showing the distribution of cells in G1, S and G2/M.  (c) Histogram chart showing 
percentages of cells in G1 derived from (a) (p<0.01). Standard deviation was 
















































Since a G1 arrest prevents entry into S phase and subsequent DNA synthesis, the 
ability of glioma cells with suppressed Ect2 protein expression to synthesis DNA was 
examined. U87MG cells were pulsed with tritiated thymidine (H3) following RNAi-
induced Ect2 down-regulation. The rate of DNA synthesis was measured on a 
scintillation counter and normalized against control or scrambled sequence siRNA 
transfected cells. The percentage of cells synthesizing DNA in Ect2 siRNA transfected 
cells was 78.4% compared to 94.3% in scrambled sequence siRNA control (Figure 4.2) 
(p<0.05, indicating that DNA synthesis was decreased  by Ect2 down-regulation. 
 
 The effect of Ect2 down-regulation on the kinetics of DNA synthesis in cells was 
also investigated using BrdU pulse chase [324, 325]. Cells were pulsed briefly with BrdU 
after siRNA transfection. One set of cells was collected immediately after pulsing to 
capture the population actively synthesizing DNA. The other set of BrdU-labelled cells 
was allowed to continue cycling and harvested 6h later. Subsequent staining with anti-
BrdU antibody and propidium iodide allowed tracking of the BrdU-labelled cell 
populations as they progressed through the cell cycle. Region gating defined the 
population of cells in S phase (Figure 4.3b). At 0h, there were 16.7% of cells in S phase 
in non-transfected cells. There were only 3.6% of cells remaining in S phase 6h later, 
indicating that 13% of cells had completed DNA synthesis. Similarly, the proportion of S 
phase cells in scrambled sequence siRNA-transfected cells decreased from 14% to 4%, 
indicating that 10% of the cells had completed DNA synthesis. In Ect2 siRNA-
transfected cells however, the percentage of S phase decreased from 13% to 10% after 

























Figure 4.2 Ect2 down-regulation decreases DNA synthesis. (a) Immunoblot showing 
efficiency of siRNA knockdown. (b) Histogram showing rate of DNA synthesis, as 























































































Figure 4.3 Ect2 down-regulation delays S phase progression. (a) Immunoblot 
showing efficiency of Ect2 siRNA silencing. (b) Scatter plots showing progression of 
BrdU-labelled cells through cell cycle following siRNA transfection. Arrows and gated 
regions indicate cells in S phase. (c) Histogram showing percentage of cells completing S 
phase as derived from gated regions in scatter plots shown in (b) (p<0.05). Standard 
















This data suggests that the G1 arrest induced by Ect2 has resulted in decreased DNA 
synthesis as well as delayed S phase progression.  
 
4.1.2 Ect2 suppression inhibits G1/S progression in re-stimulated quiescent human 
 glioma cells 
 
To characterize the G1 arrest induced by Ect2 down-regulation, U118 glioma cells 
were synchronized at G0 using serum starvation [326]. U118MG was chosen for this 
experimental model as it demonstrated the highest percentage of synchronization at G0 
using serum starvation compared to other glioma cell lines, such as U87MG (Figure 4.4a 
– b). To determine the efficiency of siRNA transfection under serum-free conditions, 
U118 cells were transfected with green fluorescence-labelled scrambled sequence control 
siRNA under 0%, 0.1% and 0.5% FBS conditions. The presence of green fluorescence in 
cells was analysed 24h after transfection. The presence of serum had minimal effect on 
siRNA uptake (Figure 4.4c).  The efficiency of Ect2 down-regulation by siRNA under 
serum-free conditions was also determined. Serum-starved U118 cells were transfected 
with Ect2 siRNA obtained from Kamijo et al [319] 24h after starvation and allowed to 
incubate for a further 48h in serum-free medium. Cells were harvested for Western 
blotting 24h after serum repletion. There was a significant suppression of Ect2 protein 
levels in Ect2 siRNA-transfected cells (Figure 4.4d). This indicates that absence of serum 


























Figure 4.4 Optimization of siRNA transfection during starvation in U118 glioma 
cells.  (a) FACS histograms showing efficiency of synchronization in U118MG and 
U87MG using serum starvation. (b) Immunofluorescence showing efficiency of siRNA 
uptake under different serum concentrations. (c) Immunoblot showing efficiency of Ect2 
silencing after serum starvation.  
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 To study the effects of Ect2 suppression on cell cycle progression in human 
glioma cells, the cells were synchronized and transfected with siRNA as mentioned 
above. Cells were released from quiescence by introducing serum into the culture 
medium and harvested for cell cycle and protein analysis at the indicated time points. 
Ect2 expression was effectively suppressed for up to 30h after serum repletion (Figure 
4.5a) In non-transfected and scrambled sequence transfected cells, S phase entry was 
initiated at around 18h, with 46% and 33% of the cells in S phase respectively (Figure 
4.5b). S phase peaked at around 24h (63% and 45%), and the G2/M boundary was crossed 
between 27 to 30h (17% and 9%). In contrast, cells transfected with Ect2 siRNA from 
two independent sources showed a prominent accumulation of cells in G1, and the G1 
arrest persisted up to 30h after serum repletion [305, 319]. At 24h, Ect2 siRNA 
transfected cells had a minimum of 73% of G1 cells, compared to 35% in non-transfected 
cells and 50% in scrambled sequence control transfected cells (Figure 4.5c). This 
demonstrates that Ect2 is required for G1/S progression. 
 
4.1.3 Ect2 alters the levels of CDK inhibitor p27Kip1 and pRb hyper-
 phosphorylation 
 
The CDK inhibitor p27Kip1 is present at high levels during quiescence and at G1 
phase of the cell cycle. In order for cells to exit quiescence and traverse across the G1/S 
border, levels of p27Kip1 must decrease [103, 327]. Since Ect2 down-regulation inhibits 
G1/S progression, the effects on levels of p27Kip1 were examined. The levels of Ect2 in 
























Figure 4.5 Ect2 is required for G1/S progression. (a) Immunoblot showing efficiency 
of Ect2 silencing at the time points indicated (N: non-transfected, SCR: scrambled 
sequence control, K: siRNA K from Kamijo et al, S: siRNA S obtained from Scoumanne 
et al [305, 319]. (b) FACS histogram showing accumulation of cells in G1 following 
siRNA transfection. (c) Bar chart comparing percentage of G1 cells at the indicated time 
points following transfection (p<0.01). Standard deviation was calculated based on three 
independent experiments. 
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scrambled sequence transfected cells (Figure 4.6a). p27Kip1 levels were high during 
quiescence in transfection control cells, but gradually decreased from 9h onwards and 
were almost un-detectable at 24h. In contrast, p27Kip1 levels remained high in Ect2 
siRNA transfected cells up till 30h following serum re-repletion (Figure 4.6b).  
 
 For cells to cross the G1/S border, they must overcome the Restriction Point. 
Beyond that, cells are committed to duplication and division of their genetic material in a 
serum-independent manner. The Restriction Point is underpinned by hyper-
phosphorylation of the retinoblastoma protein (Rb). The level of Rb phosphorylation was 
examined in cells transfected with Ect2 siRNA. The antibody used for Western analysis 
(Neomarkers Inc, clone Rb-1) detects both unphosphorylated and hyper-phosphorylated 
forms of the protein. The hyper-phosphorylated forms can be distinguished by a mobility 
shift. In transfection control cells, there was no Rb phosphorylation detectable at G0. Rb 
phosphorylation gradually increased from 6h after serum repletion and peaked at 24h 
where cells were in S phase (Figure 4.6c). However, Rb phosphorylation was 
significantly suppressed in Ect2 siRNA transfected cells. The inhibition of Rb hyper-
phosphorylation was sustained throughout 24h following serum repletion (Figure 
4.6c).Another key regulator of G1/S progression is p21Cip1. Although its expression is low 
during quiescence, p21Cip1 is rapidly induced in early G1 and regulates the activity of the 
cyclin D-Cdk4/6 complexes [93]. In non-transfected or scrambled sequence control 
transfected U118MG, p21Cip1 increased at 6h but decreased again before late G1 (Figure 
4.6d). A similar trend was observed in Ect2 siRNA transfected cells. This suggests that 
























Figure 4.6 Regulation of cell cycle proteins by Ect2 during G1/S progression. (a) – 
(d): Immunoblots showing the abundance of Ect2, p27Kip1, Rb and p21Cip1 in serum-
starved U118MG cells following siRNA transfection. (e) Immunoblots showing 
abundance of the above-mentioned proteins in asynchronous U118MG following siRNA 
transfection. N: non-transfected; S: scrambled sequence siRNA transfected; E: Ect2 
siRNA K transfected. Membranes were stripped and probed for actin as loading control.  
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 To verify that the increase in p27Kip1 by Ect2 down-regulation was not an artefact 
of cell cycle synchronization, exponentially dividing U118MG cells were transfected 
with either scrambled sequence control or Ect2-specific siRNA (K). The increase in 
p27Kip1 protein was detected at 24h following siRNA transfection and continued to 
accumulate till 72h after transfection (Figure 4.6e). The level of Rb hyper-
phosphorylation was greatly inhibited in Ect2-down regulated cells. These results also 
verify that Ect2 regulates levels of the CDK inhibitor p27Kip1 and Rb hyper-
phosphorylation.  
 
4.1.4 Effects of Ect2 over-expression on p27Kip1 
 
 The above results demonstrate that down-regulation of Ect2 results in increased 
p27Kip1 and decreased Rb hyper-phosphorylation. Ect2-mediated p27Kip1 regulation was 
further examined in cells with Ect2 over-expression to test if the reverse is true. 
Exponentially dividing U118MG cells were transfected with full-length Ect2 cloned into 
pXJ41. Ect2 over-expression was detected from 12h following transfection. The 
suppression of p27Kip1 was observed at 12h following transfection, albeit marginal. A 
parallel increase in Rb hyper-phosphorylation was also observed at 12h following 
transfection (Figure 4.7a). However, the trends ceased to occur at 24h following 
transfection. It is likely that the effect of Ect2 over-expression on p27Kip1 suppression and 
Rb hyper-phosphorylation was masked by the presence of serum and the distribution of 








Figure 4.7 Effects of Ect2 over-expression on p27Kip1 and Rb phosphorylation under 
various serum conditions. Immunoblots showing the abundance of Ect2, p27Kip1 and Rb 
following Ect2 over-expression in (a) asynchronous and (b) serum-starved U118MG 











 The interference of serum with Ect2-mediated p27Kip1 suppression was then 
investigated. The absence of serum combined with Ect2 over-expression significantly 
suppressed p27Kip1, while the suppression of p27Kip1 by Ect2 over-expression in the 
presence of serum occurred at a lesser degree (Figure 4.7b). This is consistent with the 
previous observation made in Figure 4.7a where Ect2-induced p27Kip1 suppression was 
marginal in the presence of serum and mixed cell populations.  
 
4.1.5 Ect2 over-expression drives quiescent cells through G1/S 
 
The suppression of p27Kip1 has profound effects on G1/S progression. The 
inhibition of p27Kip1 expression by anti-sense p27Kip1 results in abrogation of quiescence 
and entry into S phase [103]. To determine if over-expression of Ect2 can induce G1/S 
progression in quiescent cells, the DNA content of transfected cells under serum-starved 
conditions was examined. A striking difference between S phase populations was 
observed; with non-transfected quiescent U118MG containing a minimal 3% while 
quiescent U118MG over-expressing full-length Ect2 contained 12% S phase cells (Figure 
4.8a). These results imply that over-expression of Ect2-driven G1/S progression is 
independent of serum.  
 
 To further demonstrate that Ect2 over-expression can drive G1/S progression 
under serum-deprived conditions, DNA synthesis was determined by measuring BrdU 
incorporation. Cells were fixed and stained with anti-BrdU antibody and analysed on a 
























Figure 4.8. Ect2 over-expression induces serum-independent G1/S progression. (a, c) 
Immunoblots showing Ect2 over-expression under various serum concentrations. (b) 
FACS histogram showing distribution of cells following Ect2 over-expression with or 
without serum. (d, e) FACS and bar histograms showing percentage of BrdU-positive 
cells in serum-starved U118MG cells following Ect2 over-expression. Standard deviation 
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BrdU-positive cells than control cells 72h (0h) after incubation with BrdU (61% vs. 27%)   
 (Figure 4.8b – c). This clearly shows that Ect2 over-expression induces serum-
independent DNA synthesis. 
 
4.1.6  Mechanism of Ect2-mediated p27Kip1 suppression 
 
Fluctuations in the levels of p27Kip1 protein in a regulated manner are essential for 
progression through the cell cycle. p27Kip1 mRNA levels remain unchanged throughout 
the cell cycle and the main modes of regulation are translational and through regulating 
the stability of p27Kip1 transcript and protein [105, 145]. Here, the means by which Ect2 
regulates p27Kip1 levels are examined in greater detail. 
 
4.1.6.1 Ect2 regulates p27Kip1 transcript stability 
 
 To examine the effect of Ect2 on p27Kip1 mRNA levels, U118MG cells were 
transfected with either empty vector or full-length Ect2 under both serum-supplemented 
and serum-free conditions. Quantitative Real-Time PCR revealed that p27Kip1 mRNA 
levels in cells over-expressing full-length Ect2 protein were reduced by about 40% 
(p<0.01) compared to vector-transfected only controls under both serum-supplemented 
and serum-free conditions (Figure 4.9).  
 
The decrease in p27Kip1 mRNA following Ect2 expression shown in Figure 4.9 
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Figure 4.9 p27Kip1 mRNA is lower in cells over-expressing Ect2. (a) Immunoblot 
showing reduction of Ect2 protein levels following over-expression under both 0% and 
10% serum conditions. (b) Table showing fold change of samples (expressed as RQ: 
relative quantity) obtained from each of 5 independent sets of Real-time PCR 
experiments. (c) Histogram representation of percentage fold change calculated from (b) 

































stability. To determine the role of transcriptional regulation, cells were transfected with a 
firefly luciferase reporter plasmid containing either full-length p27Kip1 promoter (p27-PF) 
or truncated p27Kip1 promoter (p27-ApaI). pRL-TK expressing Renilla luciferase under 
the thymidine kinase promoter was co-transfected with the above plasmids for 
normalizing transfection efficiency. Luciferase activities measured for the truncated 
promoters showed low induction in both scrambled sequence siRNA and Ect2 siRNA-
transfected human glioma cells (Figure 4.10b). Compared to the truncated promoter, the 
induction of luciferase expression was significantly higher in the full-length promoter 
following scrambled sequence siRNA. The induction of luciferase under the full-length 
p27Kip1 promoter was also higher than that of the truncated promoter following Ect2 
siRNA transfection. However, luciferase activity induced by the full-length promoter 
following Ect2 siRNA transfection was not enhanced but slightly decreased in scrambled 
sequence control siRNA. It is not clear why p27Kip1 promoter activity decreased upon 
Ect2 suppression. However, this data suggests that regulation of p27Kip1 promoter activity 
is not the most crucial means by which Ect2 can suppress p27Kip1. 
 
 To determine if Ect2 regulates p27Kip1 mRNA turnover, cells were treated with 
Actinomycin D and sampled every 20 min. To minimize interference from serum and 
inherent variation in an asynchronous population, cells were synchronized at G0 and re-
stimulated with serum. As it was not known how Actinomycin D would affect the 
expression of exogenous full-length Ect2 protein, RNAi was used to manipulate the 
levels of Ect2 protein. The half-life of p27Kip1 mRNA increased from 35 min in 






















Figure 4.10 Ect2 does not modulate p27Kip1 promoter activity. (a) Immunoblot 
showing abundance of Ect2 protein following siRNA silencing. (b) Histogram showing 
relative promoter p27Kip1 promoter activity following siRNA transfection. Firefly 
luciferase signal from the full length (p27-PF) or inactive truncated promoter (p27-ApaI) 
is normalized against a reporter Renilla luciferase signal co-transfected with the 
respective promoters. Statistics were calculated based on 3 sets of independent 





























































Figure 4.11 Ect2 modulates p27Kip1 mRNA half-life. (a) Immunoblot showing 
abundance of Ect2 protein following siRNA silencing. (b) p27Kip1 mRNA abundance 
after siRNA transfection is obtained using Real-time PCR, normalized against actin 
controls and the relative abundance at the indicated time points expressed as a non-linear 
regression curve. (c) Histogram showing half-life of  p27Kip1 mRNA following siRNA 
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(Figure 4.11 b – c).  Although the standard deviation obtained from the independent 
experiments carried out was large, the general trend of increased p27Kip1 mRNA stability 
paralleled the sustained higher levels of p27Kip1 protein observed in data presented earlier 
where Ect2 suppression by siRNA resulted in higher p27Kip1 protein level. This does not 
exclude the possibility that Ect2 regulates p27Kip1 transcript stability. 
 
4.1.6.2 Ect2 regulates p27Kip1 through the proteasome  
 
 A major mode of p27Kip1 regulation is through ubiquitin-mediated degradation by 
the 26S proteasome. This is evident in the enhanced degradation of p27Kip1 protein in 
tumours. To investigate the requirement for the proteasome in Ect2-mediated p27Kip1 
protein regulation, cells were treated with the proteasome inhibitor MG132 following 
Ect2 full-length over-expression. In the presence of the inhibitor, Ect2-mediated p27Kip1 
suppression was abrogated (Figure 4.12). However, incubation with MG132 alone also 
resulted in high levels of p27Kip1. Therefore, the requirement for the Ect2-mediated 
proteasome degradation of p27Kip1 is not conclusive and will be subjected to further 
investigation. 
 
4.1.7  Ect2 promotes G1/S progression through Rho GTPase  
 
 Ect2 is required for activation of the Ras superfamily small GTPase RhoA during 
cytokinesis [268, 282, 292, 328]. RhoA regulates the G1/S progression through mediating 






















Figure 4.12 Ect2 promotes p27 degradation. Immunoblot showing the abundance of 
Ect2 and p27Kip1 following various combinations of Ect2 over-expression and proteasome 
inhibitor MG132 treatment at the indicated time points. Membrane is stripped and probed 



























factor responsible for RhoA activation in mediating the G1/S progression has not been 
identified. Since both Ect2 and RhoA regulate p27Kip1, studies were carried to determine 
if Ect2 acts as the RhoGEF for RhoA-mediated G1/S progression. Over-expression of 
Ect2 suppressed p27Kip1 protein levels while inhibition of RhoA with C3 significantly 
induced p27Kip1 protein levels (Figure 4.13a). C3 is an exo-enzyme derived from the 
bacteria Clostridium botulinum and ADP-ribosylates Asp41 in the GTPase effector 
binding domain [330]. Addition of C3 following Ect2 over-expression showed a partial 
attenuation of p27Kip1 suppression by Ect2. This suggests that Ect2 over-expression failed 
to suppress p27Kip1 in the absence of RhoA activity. Rb hyper-phosphorylation was 
increased in human glioma cells over-expressing Ect2 and inhibited in the presence of 
C3. When C3 was added to cells over-expressing Ect2, Rb hyper-phosphorylation was 
severely attenuated. This indicates that Ect2-mediated Rb hyper-phosphorylation is 
impaired in the absence of RhoA activity. 
 
To further dissect the requirement for RhoA in Ect2-mediated G1/S progression, 
the activity of RhoA upon Ect2 over-expression was measured. RhoA activity was 
determined using the Rhotekin-RBD (Rho binding domain) pull-down assay [331]. 
Rhotekin binds to activated RhoA through the RBD [332]. Thus, the level of RhoA 
activation can be determined based on the amount of RhoA protein pulled down by 
Rhotekin-RBD [333]. When human glioma cells were incubated with the RhoA inhibitor 
C3, activated RhoA pulled down by Rhotekin-RBD significantly decreased (Figure 
4.13b). However, RhoA activation was greatly enhanced upon Ect2 over-expression. 






















Figure 4.13 Ect2 promotes G1/S progression through RhoA. (a) Immunoblot showing 
abundance of Ect2, pRb and p27Kip1 following incubation with various combinations of 
Ect2 over-expression and the RhoA inhibitor C3, at the indicated time points. Membrane 
is stripped and probed with actin for loading control. (b) Immunoblot showing activated 
RhoA pulled down with the Rhotekin-binding domain (RBD) following Ect2 over-














































Ect2 protein pulled down with RhoA was higher in cells over-expressing Ect2. In the 
presence of C3 inhibition however, the amount of Ect2 detected in the Rho-Rhotekin 
RBD fraction was reduced compared to no C3 inhibition. Therefore, Ect2 over-
expression increases RhoA activation. The physical association between RhoA and Ect2 
enhances RhoA activation. These data suggest that Ect2 over-expression promotes G1/S 
progression through increased activation of RhoA. 
  
4.1.8 Effect of truncated Ect2 mutants on p27Kip1 and Rb phosphorylation 
 
 The C-terminus domains (DH and PH) of Ect2 are essential for oncogenic 
transformation in fibroblasts [295, 297]. To investigate if the DH and PH domains are 
required for Ect2-mediated p27Kip1 suppression and Rb hyper-phosphorylation, cells were 
transfected with various forms of N-terminus truncation mutants (Figure 4.14a) [298]. 
∆Ect2-DH/PH/C has the only the N-terminus removed, ∆Ect2-DH/PH has the most 
extreme end of the C-terminus removed as well leaving only the DH and PH domains, 
and ∆Ect2-DH contains only the DH domain.  
 
As indicated by the reactivity towards α-HA antibody, over-expression of Ect2 
truncated mutants in the asynchronous human glioma cells was visible only from 12h 
following transfection with no fluctuations in the endogenous Ect2 level (Figure 4.14b). 
While over-expression of full-length Ect2 showed an appreciable decrease in p27Kip1 at 
24h following transfection, the suppression of p27Kip1 following expression of the 
























Figure 4.14 DH domain is the minimum motif for suppression of p27Kip1 by Ect2. (a) 
Immunoblot showing expression of truncated Ect2 proteins in U118MG cells. (b) 
Immunoblots showing abundance of Ect2, p27Kip1 and Rb following ectopic expression of 
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Rb hyper-phosphorylation was visibly enhanced in human glioma cells transfected with 
the truncated mutants compared to vector-transfected cells. Although a general trend is 
discernable, it is not clear why the suppressive effect on p27Kip1 is subdued with the over-
expressed truncated mutants. Nevertheless, the ability of the DH/PH and DH domain 
mutants to enhance Rb hyper-phosphorylation highlights the requirement for Ect2 GEF 
activity for these two events to occur. 
 
4.1.9  Ect2 is found in the cytoplasm of quiescent human glioma cells 
 
 Early work by Miki et al using GFP-tagged Ect2 revealed that Ect2 is present 
exclusively in the nucleus during interphase and is dispersed throughout the cytoplasm as 
the nuclear envelope breaks down in mitosis [268]. The cytoplasmic localization of Ect2 
facilitates interaction with its substrate RhoA, which is a cytoplasmic protein [334]. 
However, the unique nuclear localization of Ect2 during G1 contradicts the finding in this 
study that Ect2 promotes G1/S progression through RhoA, since RhoA is only found in 
the cytoplasm.  
 
 To resolve this, the cellular localization of endogenous Ect2 was re-examined 
using biochemical fractionation. Firstly, asynchronous U118MG cells were lysed and 
extracted with either high or low-salt buffers to enrich the cytoplasmic (S2) and nuclear 
proteins (S3, P3). Micrococcal nuclease (MNase) was applied to the chromatin-bound 
fraction for DNA digestion and release of chromatin-associated proteins (S3’, P3’). 




mixed population comprising of cells in both interphase and mitosis (Figure 4.15a). The 
absence of the cytoplasmic protein MEK from the nucleus and the lack of histone H3 in 
the cytoplasm indicated that there was no cross contamination during the fractionation. 
Secondly, U118MG cells were synchronized at quiescence as previously done and re-
stimulated with serum. While total cellular Ect2 showed a cell cycle-dependent change in 
abundance in accordance with other reports, there was also the notable detection of Ect2 
in the cytoplasmic fraction during G0 and G1 (Figure 4.15b – c), indicating that there was 
Ect2 present in the cytoplasm to interact with RhoA, leading to the suppression of p27Kip1 


















Figure 4.15 Ect2 is found in the cytoplasm during quiescence. (a) Immunoblot showing the distribution of Ect2, MEK1 and 
Histone H3 in human glioma cells following biochemical fractionation. WCE: whole cell extract; S2: soluble cytoplasmic fraction; 
S3: soluble nuclear fraction; P3: insoluble chromatin-bound fraction; S3’, P3’: S3 and P3 respectively, following micrococcal 
nuclease (MNase) digestion. (b) FACS histograms showing cell cycle distribution in serum re-stimulated quiescent human glioma 
cells. (c) Immunoblot showing abundance of total cellular Ect2 and cytoplasmic Ect2 as quiescent human glioma cells re-enter cell 
cycle. Membranes are stripped and probed for actin as loading control.  
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4.2 Ect2 as a potential marker and therapeutic target of gliomas 
 
The previous experiments showed that Ect2 is essential for G1/S progression in 
human glioma cells. More importantly, Ect2 over-expression promotes glioma cell cycle 
progression through the suppression of p27Kip1 and increased Rb hyper-phosphorylation. 
These findings support a direct correlation between Ect2 expression and glioma grade 
[267, 297, 302]. This section of the study attempts to validate the feasibility of using Ect2 
as a bio-marker as well as potential target in glioma therapy. 
 
4.2.1 Ect2 promotes glioma cell invasion in vitro 
 
A distinctive characteristic of high grade glioma is invasion into surrounding 
tissues. Since Ect2 is over-expressed in high grade gliomas and plays a role in cell 
migration, the ability to enhance glioma cell invasion was examined. Full-length Ect2 
were transfected into serum-starved U118MG cells and replated. In a Boyden two-
chamber assay, U118 cells over-expressing full-length Ect2 showed greater invasion 
compared to vector only control by as much as 75% (Figure 4.16b – c). This 





























Figure 4.16 Ect2 over-expression increases glioma invasiveness. (a) Immunoblot 
showing abundance of Ect2 following cDNA transfection. (b) Representative field of 
stained U118MG glioma cells migrated across the chamber following Ect2 over-







































4.2.2 Ect2 is required for glioma cell proliferation and viability 
 
Since down-regulation of Ect2 induces G1 arrest in human glioma cells, its role in 
inhibiting glioma cell proliferation was investigated. Ect2 protein levels were suppressed 
by Day 2 of siRNA transfection at all concentrations (Figure 4.17a). At 5 nM siRNA, 
Ect2 protein levels gradually increased around Days 4 and 6, only to decrease again at 
Days 8 and 10. It is likely that long-term suppression (Days 4 onwards) by 5 nM siRNA 
was ineffective, allowing cells to resume proliferation. By Day 8, the human glioma cells 
would have reached confluency and stopped dividing, resulting in the decrease in Ect2 
protein observed. Compared to 5 nM siRNA, 20 nM siRNA suppression of Ect2 was far 
more effective, sustaining decreased protein expression up to 10 days after transfection. 
 
 The inhibition of glioma cell proliferation exhibited a dose-dependent trend, with 
the most significant inhibition at 20 nM of siRNA (Figure 4.17b). Furthermore, cells 
transfected with 20 nM of Ect2 siRNA formed 60 to 70% less clones than scrambled 
sequence siRNA transfected cells (Figure 4.17c). Taken together, these data demonstrate 
that Ect2 is important for glioma cell proliferation and clonogenecity. 
 
4.2.3 Ect2 down-regulation decreases viability of a TMZ- and γ-irradiation 
resistant human glioma cell line 
 
Chemo-resistance is a crucial issue in the use of TMZ for glioma treatment. 
























Figure 4.17 Ect2 is required for glioma cell proliferation and clonogenecity. (a) 
Immunoblots showing expression of Ect2 following siRNA silencing. (b) Survival curves 
showing viability of U118MG cells following siRNA transfection. (c) Histogram 
showing average number of colonies formed by U118MG cells following siRNA 
transfection. Error bars indicate standard deviations. Data shown are representative of 
three independent experiments (p<0.01). 
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resistant to the cytotoxic effects of TMZ [335]. Strategies developed to deal with the 
issue of TMZ resistance have met with limited success (discussed in Chapter 1.1.3.3). 
Thus better targets need to be identified, that can either increase the efficacy of TMZ or 
exhibit anti-neoplastic activity independently. 
  
 Earlier data presented in this study showed that down-regulation of Ect2 can 
inhibit proliferation and colony formation capability of human glioma cells, possibly by 
inducing G1 arrest. The anti-proliferative effect of Ect2 down-regulation was further 
examined in a MGMT-proficient p53-deficient glioma cell line T98G. As expected, 
MGMT-proficient T98G treated with TMZ alone showed little decrease in cell 
proliferation (Figure 4.18b). However, upon the addition of 10 nM Ect2 siRNA, viability 
of T98G cells decreased by nearly 40%. The concurrent use of TMZ with Ect2 down-
regulation further enhanced this growth inhibitory effect (52% vs. 61% after 72h). This 
implies while Ect2 down-regulation alone can attenuate glioma cell proliferation.  The 
concurrent use of Ect2 siRNA with TMZ can further inhibit the proliferation of TMZ-
resistant T98G cells, but only by a mere 8%. 
 
γ-Irradiation is standard treatment for GBMs, but anti-tumour effect is limited. 
There are at least two possible explanations for radio-resistance. Firstly, the clinically 
safe and relevant dose (< 60 Gy) does not effectively induce apoptosis in GBMs [336].  
Secondly, γ-irradiation-induced cell death in GBMs appears to be dependent on intact 




glioma cells potentiates the cytotoxic effects of γ-irradiation [338-340]. Unfortunately, 
p53 is mutated in at least 50% of GBMs, reducing efficacy of this treatment.  
 
 To determine if Ect2 down-regulation can enhance the effects of γ-irradiation in a 
p53-mutated human glioma cell line T98G, the cells were transfected with Ect2 siRNA 
before administration of 10 Gy of γ-irradiation. Similar to their response to TMZ, T98G 
cell proliferation did not decrease significantly in response to γ-irradiation. In contrast, 
Ect2 down-regulation alone decreased T98G cell proliferation by at least 30% (Figure 
4.18c). In cells treated concomitantly with Ect2 down-regulation and γ-irradiation, glioma 
cell viability decreased by another 10% after 72h (63% in Ect2 siRNA alone vs. 51% in 
Ect2 siRNA and 10 Gy γ-irradiation). These results suggest that Ect2 down-regulation 
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Figure 4.18 Ect2 down-regulation decreases viability of a γ-irradiation and TMZ- 
resistant human glioma cell line. (a) Immunoblot showing Ect2 abundance following 
siRNA silencing (N: no siRNA; S: scrambled sequence control; E: Ect2 siRNA K). (b – 
c) Histogram showing cell proliferation of T98G cells following combination of either γ-
irradiation or TMZ, with siRNA transfection. Statistics are calculated from a total of 4 
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CHAPTER 5: DISCUSSION 
 
5.1 Role of Ect2 in regulating G1/S progression 
  
Data from this study demonstrate a role for Ect2 in mediating the G1/S 
progression. Here, the mechanism of Ect2-mediated G1/S progression is elucidated. 
Specifically, Ect2 suppresses the CDK inhibitor p27Kip1 resulting in Rb hyper-
phosphorylation and cell cycle progression through G1/S via the RhoA GTPase.  The 
implications of this important function of Ect2 in oncogenesis and tumour progression are 
explored. 
 
5.1.1 Ect2 is a key regulator of G1/S progression 
 
 The results presented here demonstrate a role for Ect2 in regulating G1/S 
progression. Firstly, Ect2 down-regulation causes an accumulation of cells with 2N DNA 
content (Figure 4.1).  Using human glioma cells synchronized in G0, a role for Ect2 in 
promoting G1/S progression is revealed (Figure 4.5). This is consistent with a previous 
study by Scoumanne et al showing that Ect2 is required for G1/S progression in breast 
cancer cells [305]. However, the study does not propose a mechanism for this regulation.  
Furthermore, Scoumanne and colleagues characterise the role of Ect2 in G1/S progression 
in the context of a p53-induced DNA damage checkpoint, which may not be relevant to 
the events that take place during normal cell cycle progression. This aspect is addressed 
in the experimental design observing the effects of Ect2 down-regulation on cell cycle 





Secondly, findings of this study reveal the mechanism by which Ect2 regulates 
the G1/S cell cycle progression. Ect2 is required for suppression of the CDK inhibitor 
p27Kip1 through modulating the mRNA half-life and by promoting proteasome-mediated 
protein degradation (Figures 4.11 and 4.12). In serum re-stimulated G0 cells, down-
regulation of Ect2 suppresses p27Kip1 degradation, resulting in a sustained G1 arrest 
(Figures 4.5 and 4.6). The abundance of p27Kip1 observed in Ect2 down-regulated cells is 
consistent with literature demonstrating the requirement for p27Kip1 for maintaining cells 
in the quiescent stage, and that suppression of p27Kip1 is required for quiescent cells to re-
enter cell cycle upon stimulation with growth factors [103, 104, 108, 327]. p27Kip1 
inhibits the Cyclin E-CDK2 complex and the subsequent phosphorylation of Rb. [341]. 
This results in sustained repression of the E2F transcription factor by Rb leading to a 
G1/S arrest. In Ect2 down-regulated cells, the impaired hyper-phosphorylation of Rb is 
observed (Figure 4.6c), corresponding to the failure of cells to cross the Restriction Point 
and implies inhibition of kinase activity. On the contrary, Rb hyper-phosphorylation 
occurs gradually in serum re-stimulated control cells and peaks at S phase. The same 
phenomena were also observed in asynchronous cells with Ect2 down-regulation (Figure 
4.6e), demonstrating that the anti-proliferative effect of Ect2 down-regulation is not 
affected by variation in serum. 
 
In contrast, the expression of another G1 CDK inhibitor p21Cip1 is not altered by 
Ect2 down-regulation. p21Cip1 is induced at early G1 (~ 6h after serum stimulation) and 




and Ect2 down-regulated cells. Unlike p27Kip1 which is suppressed by growth factors, the 
trend of p21Cip1 expression observed in this study is consistent with a report showing the 
transient induction of p21Cip1 following growth factor stimulation [342]. Furthermore, 
p21Cip1 is generally induced by DNA damage or cellular stress under the control of p53 
[95]. Thus the results presented here provide evidence supporting the specific modulation 
of p27Kip1 CDK inhibitor by Ect2 in promoting G1/S progression.  
 
5.1.2 Role of Ect2 in regulating G1/S progression is key to its oncogenecity 
 
 Findings from this study reveal a mechanism for Ect2-mediated G1/S progression, 
specifically through modulation of the CDK inhibitor p27Kip1. The potential oncogenecity 
of Ect2 is demonstrated by two observations. Firstly, Ect2 promotes proteasome-
mediated degradation of p27Kip1 and by altering the half-life of p27Kip1 mRNA (Figures 
4.9, 4.10, 4.11 and 4.12). The suppression of p27Kip1 is associated with increased 
proliferation in several cancers [343-346]. In addition, loss of p27Kip1 through enhanced 
degradation correlates with poor patient prognosis and tumour aggressiveness [347-350]. 
Ect2 over-expression leading to enhanced p27Kip1 degradation mirrors the oncogenic 
potential of Skp2 ubiquitin ligase. Skp2 conjugates ubiquitin onto p27Kip1 phosphorylated 
at Thr187 and targets p27Kip1 for degradation by the proteasome [106, 150]. Over-
expression of Skp2 is associated with decreased p27Kip1 levels in cancers and malignant 
progression [351]. Similarly, Ect2 is also over-expressed in several cancer cell lines and 
correlates with tumour progression in gliomas [269, 302]. However, the inverse 




determined. Thus, establishing a correlation between Ect2 and p27Kip1 in patient samples 
will further support the role for Ect2-mediated G1/S progression in promoting 
oncogenesis. 
 
Secondly, the results show that Ect2 over-expression promotes cell cycle 
progression through G1/S and induce DNA synthesis under serum-free conditions (Figure 
4.8). The ability of Ect2 over-expression to confer survival advantage in serum-free 
conditions is reflective of Ras-transformed cell lines which exhibit growth factor 
independence [352]. Like-wise, cellular transformation mediated by other oncogenes is 
characterised by growth factor independence [353-359]. Furthermore, growth factor-
independence is associated with more aggressive tumour growth in vivo [360-362]. Thus, 
the ability of Ect2 over-expression to confer growth factor independence is demonstrative 
of its potential oncogenecity.  
 
5.1.3  Ect2 is the exchange factor regulating RhoA activity in cell cycle progression 
 
In this study, evidence supporting Ect2 as the exchange factor for RhoA in cell 
cycle progression is presented. Ect2-mediated suppression of p27Kip1 and Rb hyper-
phosphorylation is dependent on RhoA activity. The use of C3 inhibitor abrogates p27Kip1 
suppression and Rb hyper-phosphorylation induced by Ect2 over-expression (Figure 
4.13a). Furthermore, Ect2 over-expression increases RhoA activation and this 
relationship is underpinned by Ect2 interaction with activated RhoA (Figure 4.13b). 




activating mutations are rare [199-202, 224]. Since the activity of RhoA is determined by 
its guanine exchange factor, it is likely that deregulation of exchange activity contributes 
to RhoA-mediated transformation and oncogenesis. On the other hand, Ect2 is commonly 
over-expressed in several tumour cell lines and in high grade gliomas [269, 302]. Since 
Ect2 over-expression increases RhoA activation, it is possible that RhoA deregulation in 
certain cancers is associated with Ect2 hyper-activation of RhoA.  
 
The data presented here demonstrate that Ect2 mediates the events of G1/S 
progression through the RhoA GTPase. This is consistent with previous studies showing 
that Rho1 signalling is required for Ect2-mediated events in C. elegans. In vulva 
development of C. elegans, the anchor cells secrete growth factors to stimulate fate 
specification of the vulval precursor cells. Primary vulval fate specification is determined 
during late G1 and before S phase [363, 364]. Canevascini and colleagues demonstrate 
that Ect2 activity is required for primary vulval fate specification through Rho1 signalling 
and that expression of a dominant negative Rho1 suppresses vulva induction [304]. These 
findings further support the conclusion that Ect2 is the exchange factor regulating RhoA 
activity for G1/S events.  
 
5.1.4 Full-length Ect2 modulates p27Kip1 tumour suppressor, with DH domain 
being the functional motif 
 
In this study, evidence supporting a role for full-length Ect2 in regulating the G1/S 




p27Kip1 degradation and Rb hyper-phosphorylation (Figure 4.7). This induces cell cycle 
progression and DNA synthesis in quiescent human glioma cells (Figure 4.8). Previous 
studies on Ect2-mediated transformation and oncogenecity in nude mice involve 
expression of the N-terminus truncated Ect2 protein and demonstrate that the full-length 
exhibits no transforming potential [267, 297, 298]. Subsequently, it is hypothesised that 
N-terminal truncation of Ect2 relieves inhibition on the RhoGEF domain and 
mislocalization of the truncated protein potentiates its oncogenecity in mouse fibroblasts 
[297]. This is discordant with the in vivo situation. Firstly, over-expression of full-length 
Ect2 mRNA and protein are observed in nickel oxide-transformed mouse embryonic cells 
[299, 300]. Secondly, an in vivo model of ductal carcinoma progression in mice shows 
that full-length Ect2 cDNA amplification may be a molecular event involved in 
malignancy [301]. Consistent with the second report, increasing levels of full-length Ect2 
are detected in higher grade gliomas [302]. Thus, the use of truncated Ect2 in the study of 
mechanisms of oncogenesis in vitro is not reflective of in vivo situations.  
 
In this study, full-length Ect2 was over-expressed and the suppression of the 
p27Kip1 anti-proliferative pathway was observed. Earlier in vivo observations showed that 
Ect2 over-expression correlated with malignancy as well and induced tumourigenesis in 
nude mice. Our in vitro findings support these observations and we proposed a functional 
relationship between full-length Ect2 over-expression and oncogenecity. Our study is 
also in line with the role of another GEF, Vav1, which is commonly over-expressed in 
pancreatic cancers [266]. Previous transformation studies using truncated activated Vav1 




oncogenecity [266, 365]. In the study by Fernandez-Zapico et al, the authors demonstrate 
that ectopic expression of Vav1 activates oncogenic signalling pathways resulting in 
Cyclin D expression and cell cycle progression [266]. In addition, Canevascini et al show 
that an activating mutation in the second BRCT domain (E225K) of Ect2 leads to hyper-
induction of the primary vulva fate specification at G1 in C. elegans [304]. The gain of 
function mutation is attributed to an overall increase in normal Ect2 activity. 
Furthermore, over-expression of wild-type Ect2 is able to induce the same phenotype as 
the activating mutant. This shows that increased wild-type Ect2 expression leads to 
increase in normal activity. This is reflected in the results demonstrating increased 
activation of RhoA following full-length Ect2 over-expression (Figure 4.13b). Thus, the 
use of full-length Ect2 in this study reflects better the in vivo patient samples. 
 
In this study, various forms of Ect2 N-terminus truncation mutants were over-
expressed in human glioma cells. Full-length and three forms of Ect2 mutants (∆N-Ect2-
DH/PH/C, ∆N-Ect2-DH/PH and ∆N-Ect2-DH) promoted Rb hyper-phosphorylation with 
comparable efficiency, although the mutants suppressed p27Kip1 marginally. It is worth 
highlighting that cells expressing only the DH domain are able to hyper-phosphorylate 
Rb and suppress p27Kip1 to a certain degree. This indicates that the DH domain is 
sufficient for the mediation of these two events by Ect2. The same observation is reported 
with another exchange factor, Lbc where only the DH domain is required for 
transformation. The PH domain is not required for transformation but is essential for 




these truncation mutants are derived, also support the observation that functional domains 
of Ect2 other than DH is not required for its transforming activity [298].  
 
5.1.5 Synergism between Ect2 and other signalling pathways in transformation 
 
It is interesting to note that while over-expression of full-length Ect2 is unable to 
induce transformation in fibroblasts, it can activate oncogenic pathways in human glioma 
cells. This raises the possibility that Ect2-mediated transformation in fibroblasts requires 
co-operation with other signalling pathways such as Ras. This possibility mirrors the co-
operative effort between RhoA and Ras in inducing cellular transformation. Activating 
mutants of RhoA possess no transforming ability in mouse fibroblasts and require co-
operation with Ras signalling to induce transformation in vitro [205, 206]. Furthermore, 
studies in C. elegans reveal that Ect2 lies upstream of the Ras GEF, Sos and activates the 
Ras/MAPK signalling in response to EGF stimulation during primary vulval fate 
determination during G1 [304]. Thus, it is likely that the transforming ability of Ect2 is 
partially dependent on Ras activation and may explain why full-length Ect2 over-
expression alone is not sufficient to induce transformation in mouse fibroblasts.  
 
5.2 Potential clinical applications of Ect2 
 
 Several reports have shown that Ect2 is over-expressed in various human cancers. 
Zhang et al found that the expression of Ect2 is elevated in both pancreatic cancer tissue 




expression linked directly to Ect2 promoter methylation [367]. Hirata and colleagues also 
reported increased Ect2 expression in both non-small cell lung cancer and esophageal 
squamous cell carcinoma with the level of Ect2 protein correlating with poor patient 
prognosis [368]. In addition, Sano et al reported a similar correlation between Ect2 
abundance and patient prognosis in gliomas and findings by Roversi et al suggested that 
Ect2 over-expression is related to glioma progression [302, 369].  
 
 In this study, Ect2 was over-expressed as a full length protein in human glioma 
cell lines as seen in patient samples. Ectopic expression of Ect2 resulted in increased 
invasion of glioma cells in vitro. Conversely, suppression of Ect2 by siRNA reduced the 
viability and clonogenecity of glioma cells. This data supports the hypothesis that Ect2 
over-expression is not a mere artefact of rapidly dividing cells, but actually has an effect 
on promoting growth and invasion. As such, it enhances the feasibility of using Ect2 as a 
marker to differentiate between the proliferative and invasive GBM from the more benign 
lower grade tumours.  
 
At the same time, the potential for targeting Ect2 in chemo-resistant cells, 
particularly to that of TMZ, is explored. The proof of concept is demonstrated in Figure 
4.26 where the MGMT-proficient and p53-deficient glioma cell line, T98G is transfected 
with Ect2 siRNA. With Ect2 down-regulation alone, glioma cell viability decreases by 
nearly 40% at the end of 72h. Combined Ect2 down-regulation and TMZ reduced 
viability by a further 10%, although it is likely to be an additive effect rather than 




more pronounced anti-proliferative effect. Biochemical studies presented here also 
demonstrate that Ect2 promotes cell proliferation through suppression of CDK inhibitor 
p27Kip1, making the down-regulation of Ect2 an attractive strategy in anti-tumour 
treatment. These findings provide a foundation for which more investigation can be 














CHAPTER 6: FUTURE WORK 
 
6.1 Regulation of the G1/S progression by Ect2 
 
6.1.1 Regulation of p27Kip1 by Ect2 
 
Data presented in this study demonstrate that Ect2 regulates G1/S progression 
through modulating the levels of p27Kip1, resulting in the hyper-phosphorylation and 
inactivation of the tumour suppressor Rb (Figure 4.7). Ect2 suppresses p27Kip1 by two 
ways – decreasing mRNA half-life and promoting proteasome-mediated degradation 
(Figures 4.9 – 11). Skp2 is the ubiquitin ligase required for p27Kip1 degradation [106, 149, 
150]. Over-expression of Skp2 suppresses p27Kip1 through enhanced degradation. Skp2 
recognizes p27Kip1 phosphorylated by cyclin E-CDK2 at Thr187 and conjugates ubiquitin 
molecules onto p27Kip1 [150]. In addition, Skp2 over-expression is associated with 
decreased p27Kip1 abundance, increased aggressiveness and poor prognosis in tumours 
[370-375]. Skp2 transcription is induced by the MAPK and Akt pathways in response to 
growth stimulation [376, 377]. Furthermore, over-expression of RhoA up-regulates Skp2 
and promotes p27Kip1 degradation [318]. Since Ect2 and RhoA co-operate to promote 
G1/S progression, the status and requirement for Skp2 in this context should be further 
examined to obtain a clearer picture of p27Kip1 regulation by Ect2.  
 




p27Kip1 is a major inhibitor of Cyclin E-CDK2. Activated Cyclin E-CDK2 
phosphorylates Rb and promotes the transcription of S phase genes by E2F. At the same 
time, RhoA promotes p27Kip1 phosphorylation and subsequent degradation through 
enhanced cyclin E-CDK2 activity [147, 220]. In this study, the activity of Cyclin E-
CDK2 upon Ect2 over-expression is not clarified. How Ect2 alters Cyclin E-CDK2 
kinase activity should be investigated in greater detail so as to clearly explain the 
decrease in Rb phosphorylation. In addition, experiments should be carried to determine 
if Ect2 promotes p27Kip1 degradation in a Cyclin E-CDK2 dependent manner. 
 
6.1.3 Synergism between Ect2 and Ras/MAPK signalling in transformation and 
oncogenesis 
 
Scoumanne et al report the activation of ERK1/2 kinases in Ect2-mediated G1/S 
progression [305]. MAPK signalling is required for activation of the Cyclin D1 promoter 
during G1 and the transforming ability of Ect2 correlates with Cyclin D1 promoter 
activity [295, 378]. The homologue of Ect2 also activates Ras/MAPK signalling before S 
phase in C. elegans for promoting specification of primary vulva cell fate and the authors 
propose that Ect2 may co-operate with Ras/MAPK to induce transformation [304]. In 
addition, the expression of full-length Ect2 does not exhibit transforming activity in 
mouse fibroblasts but induces the activation of oncogenic pathways in human glioma 
cells. This raises the possibility that Ect2-activated oncogenic pathways are synergistic 
with the activation of other oncogenic pathways (discussed in detail in Section 5.3.5). To 
address this, the co-expression of Ras mutants and full-length Ect2 can be carried out in 
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mouse fibroblasts with the suppression of p27Kip1, Rb hyper-phosphorylation, foci 
formation and serum-independent DNA synthesis as end points for determining 
transformation and oncogenecity. In this study, evidence supporting Ect2 as the RhoGEF 
required for RhoA activation is presented. In addition, RhoA activity is essential for 
Ect2-mediated inactivation of p27Kip1 tumour suppressor (Figure 4.13). Thus, dominant 
negative Ect2 can be co-expressed with Ras to further clarify the relationship between 
Ect2, RhoA and Ras in cellular transformation. At the same time, MAPK inhibitors and 
constitutive active mutants can be used in conjunction with either Ect2 over-expression or 
dominant negative mutations to investigate co-operation between these two pathways. 
 
6.2 Validating clinical relevance and potential applications of Ect2 
 
In this study, in vitro data are presented proposing a role for Ect2 in G1/S 
progression. The implications of this role of Ect2 in cellular transformation and 
oncogenesis are also discussed. However, in vivo experiments must be carried to 
highlight the physiological and clinical relevance of the findings presented here. The 
directions for future work are discussed in the following sections. 
 
6.2.1 Ect2 over-expression and glioma invasion  
  
This study demonstrates that Ect2 over-expression promotes glioma cell invasion 
using a two-chamber migration assay (Figure 4.16). This result is consistent with Sano 
and colleagues’ report showing that down-regulation of Ect2 impairs glioma cell invasion 
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using the same migration assay [302]. However, the mechanism of Ect2-mediated cell 
migration is not addressed in this study. Previously, Ect2 was shown to interact with the 
Par6 polarity complex for formation of tight junctions and for determination of epithelial 
polarity [309]. C. elegans Ect2 is also required for epidermal P cell migration although it 
is not clear what the Rho GTPase substrate is [379].  
 
RhoA signalling is involved in tumour invasion and metastasis through 
modification of the cytoskeleton [380-385]. In highly metastatic hepatocellular 
carcinoma, down-regulation of RhoA inhibits the secretion of MMPs 2 and 9 and 
chemotactic migration [386]. Ect2 modifies the cytoskeleton through RhoA during 
cytokinesis but it is not clear if RhoA activity resulting in tumour invasion is dependent 
on Ect2. To address this, the effects of Ect2 over-expression or down-regulation on 
RhoA-induced MMP secretion can be measured. To further clarify the relationship 
between these two proteins in glioma cell invasion, combinations of Ect2 dominant 
negative mutants and RhoA inhibitor can be used and the extent of cell migration under 
these various combinations determined. 
 
6.2.2 In vivo models for validation of in vitro findings 
 
Ect2 over-expression promotes G1/S progression and activates oncogenic 
pathways in human glioma cells. Specifically, Ect2 suppresses the expression of p27Kip1 
and promotes Rb hyper-phosphorylation. In addition, down-regulation of Ect2 
significantly attenuates glioma cell proliferation and clonogenecity. To definitively 
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validate and demonstrate the physiological relevance of the in vitro findings of this study, 
corresponding animal studies must be carried out.  
 
6.2.2.1 Ect2 over-expression and oncogenesis 
 
 Ect2 over-expression promotes G1/S progression and induces serum-independent 
DNA synthesis in human glioma cells. The implication of this role of Ect2 in 
transformation and tumourigenesis is discussed in Section 5.3.2. However, the 
consequence of Ect2 over-expression and its role in promoting G1/S progression in 
neoplastic development is not fully addressed in this study. Firstly, to demonstrate that 
Ect2 over-expression leads to tumourigenesis, stable transfectants over-expressing Ect2 
can be generated from mouse fibroblasts and implanted intra-cranially into nude mice. 
However, the possibility that Ect2 over-expression may require co-operation from other 
signalling pathways to induce transformation and tumourigenesis should be taken into 
consideration. Tumourigenic effects of Ect2 over-expression can be determined using 
these end points: tumour volume, immunohistochemistry, proliferation index as well as 
the status of p27Kip1 in the implanted cells. 
 
The second line of study addresses the relationship between Ect2 over-expression 
and glioma progression using an in vivo model. It is shown in patients that Ect2 over-
expression correlates with tumour grading and decreased survival [302]. However, a 
causative relationship between Ect2 over-expression and these observed effects must be 
established. To demonstrate that Ect2 over-expression does indeed promote tumour 
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progression, a glioma cell line with low tumourigenecity (e.g. A172) can be stably 
expressing Ect2 and implanted intra-cranially into nude mice [387, 388]. The following 
end points should be used as a determination of tumour progression: 
immunohistochemistry of malignant phenotype, proliferation index, infiltration into 
surrounding tissues, tumour volume, mean survival rate of animal and status of p27Kip1 as 
well as MMP expression. 
 
6.2.2.2 Validating Ect2 as a potential therapeutic target 
  
Ect2 down-regulation inhibits glioma cell proliferation and clonogenecity. In 
addition, Ect2 down-regulation also inhibits growth of glioma cells resistant to TMZ and 
γ-irradiation (Figures 4.18). The next step of demonstrating the feasibility of Ect2 as a 
drug target is to reproduce the growth inhibitory effects from vitro experiments. Ect2 
siRNA can be cloned into an inducible lenti-viral vector system (GenScript Corp, 
Piscataway, NJ) and transfected into the chemo- and radio-resistant glioma cell line 
T98G [389, 390]. The stable transfectants can then be implanted into athymic mice and 
expression of Ect2 siRNA can be induced by introduction of doxycycline. Tumour 
volume and mean survival of the animals should be used as end points to determine 
efficacy of targeting Ect2. 
 
Apart from RNAi, the development of small molecule inhibitors into the 




6.2.2.3 The use of RNAi targeted against Ect2 in glioma therapy 
 
The use of RNAi in disease treatment has shown tremendous promise in animal 
models and several clinical trials are currently being conducted [391-393]. However, the 
main obstacle to achieving the desired efficacy lies in the delivery of the siRNA to the 
targeted cell type and its subsequent bioavailability [394]. In the treatment of 
neurological diseases, this problem is further compounded by the presence of the 
selectively permeable blood-brain barrier [395]. Currently several modes of siRNA 
delivery to the brain are under investigation [396]. Viral-mediated delivery is currently 
being used but non-viral mediated shRNA delivery methods are receiving increasing 
interest as well. One strategy that has achieved significant success is the use of molecular 
Trojan horses [397]. This technique takes advantage of presence of receptor-mediated 
transport (RMT) of molecules present on the brain capillary endothelial plasma 
membrane. To enhance the delivery of shRNA into the brain, the plasmid DNA is 
encapsulated in a liposome conjugated with polyethylene glycol (PEG). To facilitate 
delivery across the blood brain barrier, the PEG surface is partially conjugated with a 
receptor-specific monoclonal antibody that binds to the transport receptors on the blood 
brain barrier to initiate RMT. The efficacy of this strategy is demonstrated by Zhang et al 
where the expression of EGFR in intra-cranially implanted glioma cells is inhibited by up 
to 90% [398]. Subsequently, other groups have also improvised on this strategy to further 
enhance delivery specificity of shRNA in the treatment of brain tumours [399, 400]. The 
in vitro results presented in this study have demonstrated promise in targeting Ect2 for 
glioma therapy. However, the use of Ect2 knock-down must be placed in a clinically 
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feasible context. The use of current technology in enhancing delivery specificity and 
efficiency of shRNA in in vivo models can sufficiently address this issue and further 
highlight the clinical potential of Ect2 as a therapeutic target. 
 
6.2.3 Correlations between Ect2 and p27Kip1 in clinical samples 
 
 This study demonstrates that Ect2 over-expression results in p27Kip1 suppression 
and promotes cell cycle progression in human glioma cells in vitro. The implications of 
the role of Ect2 in mediating G1/S progression in oncogenesis and tumourigenesis are 
discussed. Ect2 over-expression was previously shown to correlate with glioma grading 
and poor patient prognosis [302]. However, clinical data demonstrating an inverse 
relationship between Ect2 and p27Kip1 expressions is lacking. Furthermore, it is important 
to establish a correlation between increased Ect2 expression and increased tumour cell 
proliferation as a result of p27Kip1 suppression as well as infiltration into surrounding 
tissues. Such clinical data will further support the use of Ect2 as a biomarker as well as 
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Ect2 is a member of the Dbl family of 
proto-oncogenes and exhibits guanine 
exchange activity for Rho-GTPases. It is 
over-expressed in dividing cells and 
tumours. Whilst Ect2 is implicated in 
oncogenesis, the mechanism is undefined. 
Using human glioma cells, we 
demonstrate the requirement for Ect2 in 
G1/S progression. Ect2 suppression 
abrogates cell cycle entry of quiescent 
glioma cells following serum repletion. 
This is accompanied by high levels of the 
CDK inhibitor p27Kip1 and reduced Rb 
hyper-phosphorylation. In contrast, Ect2 
over-expression in quiescent cells 
suppresses p27Kip1 and induces serum-
independent cell cycle progression. Ect2 
modulates p27Kip1 through mRNA 
stability and proteolytic degradation. 
Furthermore, Ect2 directs Rb hyper-
phosphorylation through RhoA. Ect2 
over-expression increases RhoA 
activation, and is parallel with increased 
binding between Ect2 and activated 
RhoA. Our findings show that Ect2 
oncogenecity is linked to its RhoGEF 
function in regulating the G1/S 
progression through degradation of the 
key CDK inhibitor p27Kip1. We 
demonstrate that inactivation of the 
p27Kip1 tumour suppressor is not 
dependent on N-terminus truncation of 
Ect2, but is dependent on the DH domain. 
We propose that Ect2 oncogenecity is 
linked to its RhoGEF function in 
regulating the G1/S progression through 
degradation of the key CDK inhibitor 
p27Kip1. 
 
Cyclin-dependent kinases (CDK) are 
indispensible for cell cycle progression. 
Antagonizing their activities are the CDK 
inhibitors (CKI). To progress through G1/S, 
cyclin E-CDK2 phosphorylates the tumour 
suppressor Rb and promotes E2F1-mediated 
transcription of S phase genes (1). Cyclin E-
CDK2 also targets the CKI p27Kip1 for 
degradation by phosphorylating Thr-187, 
facilitating recognition by the E3 ligase 
Skp2 (2,3). p27Kip1 degradation is a target of 
Ras-mediated mitogen signalling and Ras-
induced transformation (4). Not surprisingly, 
p27Kip1 degradation is enhanced in several 
tumour types and is associated with tumour 
progression and poor patient prognosis (5,6).  
RhoA GTPase is a member of the 
canonical Ras signalling pathway. RhoA 
induces assembly of focal adhesions and 
formation of actin stress fibres, as well as 
proliferative signals resulting from Ras-
mediated growth factor signalling (7,8). 
Ras-induced transformation is dependent on 
RhoA, since expression of the dominant-
negative N19-RhoA inhibits foci formation 
in V12-H-Ras transformed 3T3 cells (9,10). 
Furthermore, RhoA directly regulates G1/S 
progression through stimulating 
transcription of Cyclin D and degradation of 
p27Kip1 (11,12). Despite its importance in 
regulating cell cycle progression with 
potential for transformation, activating 
mutations of RhoA in cancers are rare.  
Rho activation is governed by cycling 
between an active GTP-bound and inactive 
GDP-bound state. The guanine exchange 
factors (GEF) catalyse this process (13), 
thus making them potential candidates for 
deregulation of Rho activity. The Epithelial 
  2 
cell transforming sequence 2 (Ect2) protein 
is required for RhoA-induced cleavage 
furrow ingression and actomyosin ring 
formation during cytokinesis (14,15). Ect2 is 
also over-expressed in high-grade gliomas 
and is implicated in cellular transformation 
through truncation of its N-terminus (16-18). 
However, the mechanism involved is 
unclear.  
In this study, we modified Ect2 
expression using siRNA and cDNA 
transfection. Although Scoumanne et al have 
shown that Ect2 regulates G1 progression 
under the control of p53 this is the first 
report demonstrating that Ect2 suppression 
inhibits G1/S progression through 
modulation of the CKI p27Kip1 and 
attenuation of Rb hyper-phosphorylation 
(19). Conversely, p27Kip1 suppression is 
achieved through increased RhoA activation 
upon Ect2 over-expression. Furthermore, we 
show that the Dbl domain is the minimum 
motif required for inactivation of the 
p27Kip1-pRb tumour suppressor. Our 
findings indicate that Ect2 over-expression 
may promote cellular transformation and 





Cell culture and transfection- U118-MG 
human glioma cells (ATCC) were cultured 
in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% foetal 
bovine serum (Hyclone). Synchronization at 
quiescence was carried out by serum 
starvation. Full-length Ect2 was transfected 
using PolyFect reagent (Qiagen). The Ect2 
truncation mutants ∆N-Ect2-DH/PH/C, ∆N-
Ect2-DH/PH and ∆N-Ect2-DH cloned in 
pCTV3-HA3 were a gift from Prof CJ Der 
(20). p27-PF, p27-ApaI, pGVB2 were gifts 
from Prof Sakai (21). siRNAs were obtained 
from sequences published by two 
independent groups (14,19) 
Western blot analysis and chromatin 
fractionation assay- Cell lysates were 
clarified by centrifugation (13,000 rpm, 20 
min, 4°C) and the protein concentration was 
determined using Bradford assay (Bio-Rad). 
The samples were separated on 6-8% SDS-
PAGE and transferred onto polyvinylidene 
difluoride membranes (Millipore). The 
membranes were incubated overnight with 
primary antibodies followed by 1 hr with 
horse radish peroxidase-conjugated 
secondary antibodies. Immuno-reactive 
bands were visualized with ECL 
chemiluminescence reagents (Amersham 
Bioscience). Chromatin fractionation assay 
to analyse sub-cellular distribution of Ect2 
was carried out as previously described (22). 
Rho activity assay- Rho activation was 
measured using the Rho Activation Assay 
Kit (Upstate Biotech) according to 
manufacturer’s protocol. RhoA activation 
and total RhoA were determined by Western 
blotting with RhoA antibody (Santa Cruz).  
Cell cycle analysis- Cell pellets were fixed 
in 70% ethanol at -20°C. Before analysis, 
cells were washed and rehydrated with 
phosphate buffered saline and stained with 
50 µg/ml propidium iodide supplemented 
with 100 µg/ml RNase A. Subsequent 
analysis was carried out on the FACS 
Calibur using the CellQuest Pro software 
(Becton Dickinson). To determine DNA 
synthesis, quiescent glioma cells were 
pulsed with 10 µM BrdU for 72h. Cells were 
fixed as above, stained with anti-BrdU 
antibody (BD Pharmigen) and analysed on 
the FACS Calibur. 
cDNA Synthesis  and Real-Time RT-PCR- 
RNA was extracted from cell pellets using 
Tri Reagent (Molecular Research Centre) 
according to manufacturer’s protocol. 500 
ng of total RNA was used for 1st strand 
cDNA synthesis using Improm-II reverse 
transcriptase (Promega) and the 1st strand 
cDNA was subsequently used as the 
template for Real-Time RT-PCR. The 
following primers were used for detecting 
p27Kip1 mRNA levels, sense: 5' - AAC CGA 
CGA TTC TTC TAC TC - 3' and anti-sense: 
5' - GAT GTC CAT TCC ATG AAG TC- 
3'. Briefly, 2 µl of cDNA template and 1 µM 
of each primer were added to Quantitect 
SYBR Green PCR mix (Qiagen) and 
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allowed to cycle on the DNA Engine 
Opticon (Bio-Rad) at the following 
parameters: a pre-denaturing step at 95ºC for 
10 min, followed by 45 cycles of 
denaturation at 95ºC for 1 min, annealing at 
55ºC for 30 sec, and extension at 72ºC for 1 
min. Absolute amounts of transcripts were 
calculated using CT values obtained and 
normalized against actin control. Student’s t-
test was used to calculate statistical 
significance. 
Assay of mRNA stability- Cells were treated 
with Actinomycin D (Sigma) and total RNA 
was harvested at the time points indicated. 
Abundance of p27Kip1 transcripts were 
determined by Real-time RT-PCR and 
normalized against that of actin control.  
Luciferase reporter assay- Cells were co-
transfected with the indicated reporter 
plasmids and pTK-RL expressing Renilla 
luciferase at a ratio of 1:20 (Promega). 
Measurement of promoter activity was 
carried out using the Dual Luciferase Assay 





Down-regulation of Ect2 impedes G1/S 
cell cycle progression.  To clarify the role of 
Ect2 in cell cycle regulation, quiescent 
human glioma cells were transfected with 
Ect2 siRNA and analysed for cell cycle 
progression following serum repletion. In 
non-transfected and scrambled sequence 
transfected cells, DNA synthesis was 
initiated at around 18h with S phase peaked 
at around 24h. The G2/M boundary was 
crossed between 27 to 30h (Fig. 1a). In 
contrast, cells transfected with independent 
Ect2 siRNAs showed a prominent 
accumulation of cells in G1, persisting up to 
30h after serum repletion. In particular, Ect2 
siRNA transfected cells contained ≈ 73% of 
G1 cells, compared to 35% in non-
transfected cells and 50% in scrambled 
sequence control transfected cells 24h after 
serum repletion (p<0.05)  (Fig. 1b). This 
demonstrates that Ect2 is required for G1/S 
progression.  
Ect2 down regulation-induced G1 arrest 
is accompanied by increase in p27Kip1 and 
decrease in Rb phosphorylation. Expression 
of the CDK inhibitor p27Kip1 is elevated 
during quiescence and its degradation is 
required for cell cycle re-entry and 
subsequent G1/S progression (23). We 
investigated whether down-regulation of 
Ect2 altered p27Kip1 protein levels. 
Expression of Ect2 protein was inhibited 
following siRNA transfection compared to 
non-transfected and scrambled sequence-
transfected cells (Fig. 2a). In non-transfected 
and scrambled sequence-transfected cells, 
the levels of p27Kip1 gradually decreased as 
quiescence-synchronised cells re-entered the 
cell cycle and progressed into S-phase upon 
serum repletion. In contrast, p27Kip1 protein 
levels in Ect2 siRNA-transfected cells 
remained high and persisted till 24h 
following serum repletion (Fig. 2b). In 
contrast, the other CDK inhibitor p21Cip1 did 
not change with the manipulation of Ect2 
protein expression. 
Phosphorylation and inactivation of pRb 
is critical for G1/S progression. Thus, we 
determined the phosphorylation status of 
pRb in Ect2 down-regulated human glioma 
cells. pRb phosphorylation was defined by 
mobility shift. During quiescence, Rb was 
present as the hypo-phosphorylated form in 
control and scrambled sequence-transfected 
cells. The hyper-phosphorylated form 
appeared at 6h following serum repletion 
and peaked at 24h when cells were entering 
S phase. In contrast, Rb phosphorylation 
was significantly delayed in Ect2 siRNA-
transfected cells, with no detectable Rb 
hyper-phosphorylation until 12h following 
serum repletion (Fig. 2c). After 12h, Rb 
phosphorylation in Ect2 siRNA-transfected 
cells was also significantly lower than the 
level observed in control cells. These 
demonstrate that Rb hyper-phosphorylation 
is greatly impaired throughout G1 phase by 
Ect2 down-regulation. p21Cip1 protein 
abundance did not fluctuate with Ect2 
suppression (Fig. 2d). 
Ect2-mediated p27Kip1 suppression is 
serum-independent. Our data show that Ect2 
down-regulation in serum-free conditions 
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impaired cell cycle re-entry and inhibited G1 
progression through increased p27Kip1 
protein levels. We examined if Ect2 over-
expression suppressed p27Kip1. Full-length 
Ect2 was over-expressed in asynchronous 
glioma cells. Within 6h of cDNA 
transfection, the level of p27Kip1 protein 
showed a gradual decrease whereas its level 
remained unchanged in non-transfected 
samples. We also observed corresponding 
increased Rb phosphorylation from 
following Ect2 over-expression (Fig. 3a). 
However, Rb phosphorylation was 
independent of Ect2 over-expression at 24h. 
This is likely due to the mixed cell 
population used.  
Next, we asked if the suppression of 
p27Kip1 by Ect2 was serum-dependent. Cells 
were starved and transfected with the 
pXJ41-Ect2 plasmid. p27Kip1 was suppressed 
in cells transfected with full-length Ect2 
regardless of the presence of serum (Fig. 
3b). These results show that Ect2 suppresses 
p27Kip1 protein and promotes Rb 
phosphorylation independent of serum. 
Ect2 over-expression induces cell cycle 
progression in quiescent glioma cells. 
Suppression of p27Kip1 and hyper-
phosphorylation of Rb had profound effects 
on cell cycle progression. To determine the 
effects on cell cycle progression, Ect2 
expression was induced in quiescent glioma 
cells. Under serum-free conditions, cells 
expressing exogenous Ect2 contained a 
higher percentage of S-phase cells than the 
vector transfected control (12% vs. 3%), 
although the difference was not as marked in 
the presence of serum (Fig. 4a). It is possible 
that the effects of Ect2 over-expression on 
cell cycle were masked by the presence of 
serum.  
To analyse the effect of Ect2 over-
expression on DNA synthesis, quiescent 
glioma cells were pulsed with BrdU 
following Ect2 transfection for 72 hr and 
analysed using flow cytometry. Cells over-
expressing Ect2 contained a markedly 
higher percentage of BrdU-positive cells 
than control cells 72h after over-expression 
of Ect2 (61% vs. 27%), demonstrating that 
Ect2 over-expression induces serum-
independent DNA synthesis in quiescent 
glioma cells (Fig. 4b). 
Ect2 regulates p27Kip1 abundance at 
mRNA and protein levels. To determine how 
p27Kip1 is regulated by Ect2, we measured 
the amount of p27Kip1 transcripts by Real-
Time RT-PCR. p27Kip1 mRNA levels 
decreased upon over-expression of Ect2 
regardless of the presence of serum (Fig. 
5a). To exclude transcriptional regulation, 
full-length and truncated p27 promoters 
were transfected and the luciferase activities 
measured. Ect2 siRNA transfection failed to 
increase full-length p27Kip1 promoter activity 
and further inhibited p27Kip1 promoter 
activity (Fig. 5b). Thus, it is not likely that 
Ect2 down-regulates p27Kip1 mRNA at the 
transcription level.  
Since stability of mRNA also influenced 
p27Kip1 abundance, we asked if Ect2 down-
regulation prolonged the half-life of p27Kip1 
mRNA.  Cells transfected with control or 
Ect2 siRNA were treated with Actinomycin 
D to inhibit de novo transcription. p27Kip1 
mRNA at various time points was quantified 
with Real-Time RT-PCR. The half-life of 
p27Kip1 mRNA increased from 35 min in 
scrambled sequence control siRNA-
transfected cells to 51 min in Ect2 siRNA-
transfected cells (p <0.05) (Fig. 5c – d). Our 
results demonstrate that Ect2 down-
regulation prolongs the half-life of p27Kip1 
mRNA. 
We tested the requirement of 
proteasome in Ect2-mediated p27Kip1 
suppression by using the proteasome 
inhibitor MG132. Over-expression of Ect2 
alone was sufficient to reduce p27Kip1 levels 
to below basal levels in control cells. 
However, addition of MG132 to cells over-
expressing Ect2 completely abrogated the 
suppression of p27Kip1 (Fig. 5e), indicating 
that Ect2 is dependent on the proteasome for 
p27Kip1 regulation. 
Ect2 promotes G1/S progression through 
the small GTPase RhoA. RhoA mediates 
G1/S progression through suppression of 
p27Kip1. However, its activating GEF is 
unidentified. Since the GEF Ect2 suppresses 
p27Kip1 to promote G1/S progression, we 
examined if RhoA activity is required for 
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these events. Over-expression of Ect2 
suppressed p27Kip1 and increased Rb hyper-
phosphorylation. Incubation with RhoA 
specific inhibitor C3 in cells over-expressing 
Ect2 partially restored p27Kip1 protein level 
and Rb hyper-phosphorylation was 
completely suppressed (Fig. 6a).  
We further defined the relationship 
between RhoA activation and Ect2 over-
expression by performing a Rho activation 
assay. In the presence of C3, RhoA 
activation was abrogated (Fig. 6b). RhoA 
activity increased significantly following 
Ect2 over-expression and C3 failed to 
attenuate RhoA activity at the concentration 
tested. Furthermore, Ect2 association with 
activated RhoA increased with Ect2 over-
expression. The presence of C3 slightly 
reduced the amount of Ect2 associated with 
activated RhoA. Our results show that Ect2 
over-expression increases RhoA activation 
and this relationship is highlighted by the 
interaction between Ect2 and activated 
RhoA. 
The DH domain is required for 
suppression of p27Kip1 by Ect2. The N-
terminal truncated form of Ect2 induces 
malignant transformation in mouse 
fibroblasts with unknown signalling 
pathways underlying Ect2 oncogenecity. We 
investigated whether the deletion of N-
terminal regions affected Ect2-mediated pRb 
phosphorylation and suppression of p27Kip1. 
p27Kip1 protein level decreased in cells over-
expressing the various truncation mutants 
(Fig. 7). Rb phosphorylation was enhanced 
in the cells with over-expression of the 
different truncation mutants. Particularly, 
cells expressing ∆Ect2-DH exhibited the 
same pattern of p27Kip1 suppression and pRb 
hyper-phosphorylation as the full-length, 
∆N-Ect2-DH/PH/C or ∆N-Ect2-DH/PH 
albeit at a lower level of expression. These 
results show that the DH domain is the 
minimal function motif required for Ect2 to 
suppress p27Kip1. Neither PH domain nor N-
terminal (BRCT domain) truncation is 
necessary for promoting the G1/S transition 
through p27Kip1. 
Ect2 is found in the cytoplasm during 
quiescence. Previously Ect2 was reported to 
be present in the nucleus during interphase 
and dispersed to the cytoplasm during 
mitosis (16). This creates a conundrum 
whereby the cellular location of Ect2 
contradicts its activation of RhoA during 
G1/S demonstrated earlier. To address this, 
we analysed the location of Ect2 in U118 
glioma cells. Ect2 was found in both 
cytoplasmic and nuclear fractions during 
interphase (Fig. 8a). Surprisingly, Ect2 was 
found in the chromatin-bound fraction, 
indicating either direct or indirect interaction 
with DNA. Further tracking of Ect2 
localization as quiescent cells were 
stimulated to re-enter cell cycle revealed that 
low amounts of the protein was present in 
the cytoplasm during G0/G1 (Fig. 8b). The 
cytoplasmic fraction increased as cells 
progressed towards mitosis. This finding, 
although contradictory to previous studies 
showing the unique localization of Ect2 in 
the nucleus during G1, resolves the issue of 
how Ect2 is able to activate cytoplasmic 




While other in vitro studies show that N-
terminus truncation activates Ect2 as an 
oncogene, they do not account for the 
detection of only the full-length protein in 
tumours (16,17,20). Also, not all RhoGEFs 
are oncogenically activated by truncation. 
For instance, Vav1 is a RhoGEF over-
expressed in several cancers as a full-length 
protein but there are no reports of the 
truncated oncogenic form (24-26). Ectopic 
expression of the full-length protein 
activated oncogenic signalling pathways, 
induced cyclin D1 expression and cell cycle 
progression (27). Our observations of full-
length Ect2 mirror that of Vav1. Thus the 
manipulation of full length Ect2 protein in 
this study better reflects the in vivo situation 
compared to previous models utilizing the 
truncated forms. 
Canevascini et al showed that 
expression of the gain-of-function Ect2 
mutant in C. elegans resulted in hyper-
induction of the primary vulva fate 
specification at G1, a process that is 
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dependent on Ras and Rho-1 activity (28). 
Over-expression of the full-length Ect2 
protein induced the same phenotype. Thus, 
the activation of proliferative signalling 
pathways by Ect2 is likely to be the result of 
an increase in normal Ect2 activity. Our data 
demonstrating increase in activated RhoA 
and inhibited p27Kip1 tumour suppressor 
pathway following full-length Ect2 over-
expression supports this hypothesis, and 
provides a possible mechanism for the role 
of full-length Ect2 in regulating the G1/S 
progression as well as in malignant 
transformation.  
 However, this raises the question of 
how expression of transfection of full-length 
Ect2 in NIH3T3 cells failed to induce a 
transformed phenotype. It is possible that 
Ect2-mediated transformation in vitro 
requires the co-operation of other signalling 
pathways such as Ras. This hypothesis 
mirrors the co-operative effort between Rho 
and Ras to induce transformation; by itself 
activated Rho does not result in a 
transformed phenotype but is potent when 
activated Ras is co-expressed (10,29). 
Furthermore, studies in C. elegans show that 
Ect2 lies upstream of Sos, and activates the 
Ras/MAPK signalling in response to EGF 
(28).  Thus, it is likely that transforming 
potential of Ect2 is partially dependent on 
Ras and explains why Ect2 over-expression 
alone is not sufficient to induce a 
transformed phenotype. 
 In summary, our work helps to 
determine a functional role for the observed 
over-expression of full-length Ect2 in 
gliomas. Based on our findings, we propose 
a mechanism by which Ect2 promotes 
oncogenecity through regulating the key 
CDK inhibitor p27Kip1. The finding that Ect2 
over-expression de-regulates RhoA activity 
during cell cycle progression addresses the 
issue of the absence of activating RhoA 
mutants in human tumours. The data 
presented here forms the basis for further 
investigation; including potential 
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 Fig. 1. Ect2 knockdown impedes cell cycle progression. A. FACS histograms showing the 
effect of Ect2 suppression on cell cycle entry in re-stimulated quiescent human glioma cells. 
siRNA K is obtained from Kamijo et al and siRNA S is obtained from Scoumanne et al (14,19). 
B. Histogram comparison of percentage of G1 cells. Asterix denotes persistence of G1 cells in 
Ect2 siRNA transfected cells. Error bars indicate standard deviations. Data shown are 
representative of three independent experiments. 
 
 Fig. 2. Ect2 down-regulation up-regulates p27Kip1 protein and impairs Rb hyper-
phosphorylation. Immunoblots showing changes in p27Kip1 abundance and Rb phosphorylation 
in serum-stimulated quiescent glioma cells. Lysates were collected at the indicated time points 
and subjected to denaturing SDS-PAGE. 
 
 Fig. 3. Ect2 over-expression suppresses p27Kip1. A. Protein lysates were collected at the 
indicated time points following transfection of pXJ41-Ect2 full length and analyzed using 
Western blotting, and immunoblotted for p27Kip1, Rb, p21Cip1 and Ect2. Actin was used as a 
loading control. B. U118 glioma cells were starved for 24h before transfection with pXJ41-Ect2 
full length and collected 48 h later for protein analysis.  
 
 Fig. 4. Ect2 over-expression induces serum-independent DNA synthesis. A, B. FACS 
histograms showing the effects on Ect2 over-expression on cell cycle progression and DNA 
synthesis. U118MG cells were transfected with either empty plasmid or full-length Ect2 under 
serum-starved or serum-supplemented conditions. Standard deviations were calculated based on 3 
independent experiments.  
 
 Fig. 5. Ect2 over-expression promotes p27Kip1 degradation. A. Histogram showing the 
effect of Ect2 over-expression on p27Kip1 transcript abundance. Standard deviations were 
calculated based on 5 sets of independent experiments (*: p<0.01, **: p<0.5) B.  Histogram 
displaying relative luciferase activities normalized against background from empty reporter 
plasmid. Standard deviations were calculated from 3 independent experiments (p<0.05). C. Cells 
were incubated with Actinomycin D to halt transcription. p27Kip1 mRNA abundance was 
expressed as a non-linear regression curve where the half-life (D) was derived from (n=3, 
p<0.05). E. immunoblot showing the effect of Ect2 over-expression and proteasome inhibition on 
p27Kip1 degradation. 
 
 Fig. 6. Ect2 activates RhoA to suppress p27Kip1. Immunoblots showing the activation of 
RhoA by Ect2. Cells were transfected with pXJ41 plasmid expressing full length Ect2. C3 was 
added at 10 µg/ml 24 h later and cells were collected for protein analysis at the indicated time 
points. Rhotekin-binding assay was performed to pull down activated RhoA upon Ect2 over-
expression. WCE: whole cell extract. 
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 Fig. 7. Ect2 DH domain alone is sufficient to suppress p27Kip1. Immunoblots showing the 
effect of over-expression of either pXJ41-Ect2, ∆N-Ect2-DH/PH/C, ∆N-Ect2-DH/PH and ∆N-
Ect2-DH on p27Kip1 abundance and Rb hyper-phosphorylation. Ect2 was detected with either anti-
Ect2 antibody or anti-HA antibody. Actin was used as a loading control.  
 
 Fig. 8. Ect2 is found in both cytoplasmic and chromatin-bound fractions during 
interphase. Immunoblots showing the distribution of Ect2 in cellular compartments using low and 
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Figure 5 
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TARGETTING THE GEF ECT2 IN ADJUVANT THERAPY WITH IRRADIATION AND 
CONVENTIONAL CHEMOTHERAPY 
Cheng SY1, Wang TT1, Zhu CJ1, Wong MC2 
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2
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Aims: To show that (i) suppression of Ect2 (Epithelial cell transforming protein 2) leads to 
decreased cell proliferation by cell cycle arrest and inhibiting RB phosphorylation and (ii) 
treatment with Ect2 siRNA sensitizes human glioma cells to irradiation and temozolomide 
(TMZ). 
Methods: Human glioma cells were synchronized by serum depletion for 72 hr and Ect2 protein 
expression was suppressed by transfecting siRNA into human glioma cells. Cell proliferation was 
measured by MTT colorimetric assay while cell cycle phase was determined using propidium 
iodide staining and FACS analysis. Western blot analysis was done to determine the degree of Rb 
phosphorylation. Cells were exposed to 10 Gy of γ-irradiation and 100 µM TMZ. 
Results: Human glioma cells transfected with control siRNA or no siRNA were able to progress 
through cell cycle after release from quiescence while cells transfected with Ect2 siRNA were 
arrested at G1 phase. Western blot analysis showed that Rb was hypo-phosphorylated, indicating 
that cells were unable to cross the restriction point. There was also a significant decrease in cell 
proliferation in Ect2-suppressed cells. 
 
